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ABSTRACT OF DISSERTATION

PCB DISRUPTION OF GUT AND HOST HEALTH: IMPLICATIONS OF
PREBIOTIC NUTRITIONAL INTERVENTION
Exposure to environmental pollutants poses numerous risk factors for
human health, including increasing incidence of cardiovascular disease and
diabetes. Persistent organic pollutants, such as polychlorinated biphenyls
(PCBs) have been strongly linked to the development of these chronic
inflammatory diseases and the primary route of exposure is through
consumption of contaminated food products. Thus, the gastrointestinal tract
is susceptible to the greatest levels of these pollutants and is an important
facet to study.
The first two hypotheses of this dissertation tested that exposure to PCBs
disrupts gut microbiota directly (in vitro) and within a whole body system.
PCB exposure disrupted microbial metabolism and production of metabolites
(i.e. short chain fatty acids) in vitro. These disruptions in microbial
populations were consistent in our mouse model of cardiometabolic disease,
where we observed reductions in microbial diversity, an increase in the
putative pro-inflammatory ratio of Firmicutes to Bacteroidetes, and reductions
in beneficial microbial populations in exposed mice. Furthermore, observed
greater inflammation was observed both within the intestines and
peripherally in PCB exposed mice as well as disruptions in circulating
markers associated with glucose homeostasis.
Nutritional interventions high in prebiotic dietary fiber such as inulin may
be able to attenuate the toxic effects of pollutant exposure. To test the
hypothesis that consumption of the prebiotic inulin can decrease PCBinduced disruption in gut microbial and metabolic homeostasis, LDLr-\- mice
were fed a diet containing inulin and exposed to PCB 126. Mice fed an
inulin-containing diet and exposed to PCBs exhibited improved glucose
tolerance, lower hepatic inflammation and steatosis, and distinct differences

in gut microbial populations. Overall, these data suggests that nutritional
intervention, specifically prebiotic consumption, may reduce pollutantinduced disease risk.
KEYWORDS: Gut Microbiota, Cardiometabolic disease, PCBs, Inulin,
Prebiotic, Nutrition
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Chapter 1

Literature Review

Annals of the New York Academy of Sciences: PMID: 28574588
Sections 1.1 – 1.2.3
Jessie B. Hoffman, Bernhard Hennig [1]
1.1

Environmental Pollutants: Overview
Environmental pollution affects nearly every country throughout the world,

and exposure to environmental pollutants is involved in the pathogenesis of
numerous non-communicable diseases including cardiovascular disease,
diabetes, and obesity [2]. Recent evidence from the World Health Organization
has revealed that China and India are two of the most affected countries in terms
of indoor and outdoor air pollution exposures with approximately 6.5 million
associated deaths each year [3]. Pollution from non-airborne exposures (e.g.,
contaminated foods and waters) are more difficult to determine but should be
expected to further increase these high death rates. Despite our knowledge of
the adverse health effects of pollution exposure, levels of environmental
pollutants have continued to rise over the past few years, especially in
developing countries. Great strides have been made over the past decade to
substantially reduce the amount of pollution generated and while total elimination
is ideal, it is not a realistic or feasible goal in the immediate future [4]. The next
question then becomes what can we do now, as individuals, to protect ourselves
and future generations from pollutant toxicity and associated diseases? Thus, if
we can better understand the mechanisms associated with exposure to
environmental pollutants and effects on disease risk we may be able to develop
appropriated and effective means to tackle such issues.

1

1.1.1 Effects of Pollutants on the Human Body
Pollutants impact nearly every system of the human body. We are exposed to
pollution through a variety of routes including air, the water we drink, and the
foods that we consume [2, 5]. These routes of exposure introduce complications
throughout the pulmonary system, digestive tract, liver and circulation, and
ultimately impact peripheral tissues [2]. The impact of exposure within these
systems contributes not only to localized inflammatory responses, but may also
influence whole-body metabolic, vascular, and immune health, thus increasing
the risk of non-communicable diseases.
Pulmonary System
One common route of pollutant exposure is through inhalation, thus exerting
detrimental effects on the pulmonary system [5]. Exposure to air pollution has
been consistently linked with the development of conditions including asthma,
chronic obstructive pulmonary disease, and respiratory infections [6]. There is a
well-documented interplay between air pollution exposure and increased airway
reactivity in children with asthma, and chronic exposure may also increase the
risk of asthma development in children [6, 7]. Furthermore, exposure to air
pollutants during gestational and early life has also been associated with
disturbances in lung development and prevalence of respiratory conditions in
childhood that may persist throughout life [8]. For example, short-term exposure
to particulate matter (PM2.5), NO2, and ozone, is associated with lower forced
vital capacity and lower forced expiratory volume [9]. Additionally, a recent study
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reported that in adult patients with acute respiratory distress syndrome, chronic
exposure to air pollution (i.e. ozone and particulate matter) is associated with an
increase rate of mortality [10]. Importantly, the initiation of inflammatory
responses within the lungs from pollutant exposure can impact other organ
systems, contributing to further disease pathologies [11]. For example, acute or
chronic exposure to airborne particulate matter can accelerate the pathology of
atherosclerosis through increases in vascular inflammation, macrophage
infiltration, and generation of reactive oxygen species [12, 13].
Gastrointestinal Tract
The gastrointestinal tract plays critical roles in human health and has recently
garnered more attention in the scientific community, specifically regarding the
intestinal barrier and gut microbiome. The principle function of the intestine is to
regulate the absorption of water and nutrients into circulation while also serving
as a barrier to the infiltration of pathogens and toxic compounds [14].
Additionally, the gut harbors trillions of bacteria that play critical roles in
numerous facets of host metabolism and health [15]. Alterations in gut microbial
composition is termed “dysbiosis” and has been linked to increased disease risk.
These perturbations in gut microbial populations are associated with a decrease
in microbial diversity and are observed in conditions of obesity and diabetes [15].
Importantly, there is current evidence that an altered gut microbiome may
actually be causal in the development of such chronic inflammatory
conditions.[16, 17] Because the primary routes of exposure to many pollutants is
through water and foods, the gastrointestinal tract is exposed to high levels of
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pollutants and thus be greatly affected. Indeed, it has been observed that
exposure to polychlorinated biphenyls (PCBs) disrupts intestinal barrier function
through dysregulation of tight junction proteins [18]. Furthermore, oral exposure
to the pollutant benzo[a]pyrene resulted in intestinal inflammation and ileal
lesions, which was associated with shifts in gut microbial composition [19].
Importantly, Zhang et al [20] have demonstrated that exposure to the persistent
organic pollutant tetrochlorodibenzofuran (TCDF), can result in alterations of gut
microbial populations at the level of phylum, class, and genus and these changes
were associated with disruptions in bile acid and short chain fatty acid (SCFA)
metabolism [20]. This study is one of the first to indicate the link between the
effects of pollutant exposure in the gut to overall metabolic health.
While it is commonly thought that air pollution only affects lung health, it is
important to note that this exposure can also affect the digestive tract and
subsequently systemic organ systems. It has been documented that upon
inhalation, airborne pollutants are quickly cleared from the lungs and transported
to the intestine via mucociliary transport [14]. Therefore, even airborne pollutants
can alter overall gut health and microbial populations. For example, it has been
demonstrated that ingestion of airborne particulate matter (PM) can cause
intestinal inflammation and alter the gut microbiota, contributing to alterations of
SCFA production in mice [21]. Additionally, in colonic cells, exposure to PM
caused reactive oxygen species production, nuclear factor kappa-b (NF-κB)
activation, and disruptions in tight junction proteins, indicating that PM may
disrupt intestinal permeability and increase intestinal inflammation [22]. Because
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the gut lies at the interface of the outside environment and our internal organ
systems, maintenance of a healthy intestinal environment and microbiome may
aid in prevention of pollutant-associated diseases.
Liver
Many nutrients and toxicants travel from the gut to the liver via the portal vein.
Thus, the liver is one of the most critical organs in the body, contributing greatly
to metabolism, secretory, excretory, and vascular functions. In the United States,
the incidence of liver disease has increased with expanding levels of obesity and
is thought to be due to an increase in non-alcoholic fatty liver disease (NAFLD)
and non-alcoholic steatohepatitis (NASH) [23]. While these liver pathologies can
be developed through poor dietary and lifestyle choices, there is recent evidence
that environmental pollutants can also greatly influence liver disease [24]. The
term, toxicant-associated fatty liver disease (TAFLD) is a relatively new labeled
type of liver disease and exhibits similar pathologies to other liver diseases [24].
TAFLD and its more severe form, toxicant associated steatohepatitis (TASH),
have been observed in workers highly exposed to industrial chemicals such as
vinyl chloride [25]. These observations of TASH were associated with increased
levels of inflammatory cytokines as well as insulin resistance, indicating the
widespread metabolic complications that pollutant exposure can exert via the
liver [25]. Furthermore, there is evidence that low-level pollutant exposure may
also influence the development of liver pathologies. For example,
epidemiological data from the general population revealed associations between
PCBs and increased levels of serum alanine aminotransferase (ALT), a widely
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used biomarker of liver injury [26]. These findings support a potential association
of chronic, low level pollutant exposure and the development of TAFLD and liver
disease. Because the liver is such a vital organ for metabolism, environmental
exposures affecting the liver may also contribute to obesity and diabetes through
disruption in glucose and lipid metabolism. Therefore, further research is
warranted to better understand the mechanisms behind pollutant-induced liver
injury and avenues of potential protection against these pathologies.
Vascular Tissues
Circulating nutrients, toxicants, and their metabolites can modulate vascular
responses that can either be pro- or anti-atherogenic. One of the key events in
the progression of atherosclerosis is endothelial cell dysfunction. It has been
documented that exposure to particulate matter (PM) air pollution can disrupt the
vasculature resulting in endothelial cell dysfunction [27]. Furthermore, there is
also evidence that arsenic exposure is associated with endothelial cell
dysfunction, as evidenced by the presence of circulating soluble intercellular
adhesion molecule-1 (sICAM-1) and soluble vascular cell adhesion molecule-1
(sVCAM-1) in Bangladeshi individuals exposed to arsenic [28]. In support of this,
in mouse models of atherosclerosis (APOE-/-), exposure to arsenic resulted in
increased accumulation of arsenic within the vessel walls as well as exacerbated
aortal lesion formation [29]. There is also evidence that persistent organic
pollutants (POPs), including PCBs, can increase atherosclerotic risk.
Specifically, coplanar PCBs such as PCB 77 and PCB 126 bind to the aryl
hydrocarbon receptor (AhR) within vascular endothelial cells, triggering a
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cascade of events that leads to production of reactive oxygen species and
disruption of cellular redox status [30]. These events ultimately lead to upregulation of NF-κB resulting in induction of proinflammatory gene products such
as cytokines, chemokines, and cell adhesion molecules that contribute to
endothelial cell dysfunction and the early stages of atherosclerosis [31]. More
recent evidence suggests that dioxin-like pollutant exposure (PCB 126) can
result in up-regulation of the enzyme flavin-containing monooxygenase 3 (FMO3)
and subsequently increase circulating levels of trimethylamine-N-oxide (TMAO),
a biomarker strongly associated with cardiovascular disease [32].
Peripheral Tissues
Upon circulation of these environmental pollutants, as discussed above,
numerous peripheral tissues become exposed, including highly vascularized
adipose tissue [33]. With the worldwide obesity epidemic, research on the
toxicological interplay between pollutants and adipose tissue has become
increasingly important. It is no longer believed that adipose tissue is solely a
storage of excess energy, but in fact plays numerous metabolic and endocrine
roles within the body. In regards to pollutant exposure, adipose tissue is capable
of storing lipophilic pollutants, specifically persistent organic pollutants (POPs)
[33]. While such storage can be protective to reduce availability to other organ
systems in situations of acute and high pollutant exposures, there is evidence
that a low and chronic release of POPs from adipose tissue can exert some toxic
effects to other lipophilic tissues such as the brain and the liver [34].
Furthermore, it has been demonstrated that pollutants can alter adipose tissue
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structure and function through metabolic disruption and inflammation, which may
increase the risk of chronic metabolic diseases [33, 35]. Some pollutants also
have been associated with increases in adiposity and weight gain and are thus
termed “obesogens” [36]. These pollutants, including bisphenol A (BPA),
benzo[a]pyrene, and certain organophosphate pesticides, are thought to play a
role in the development of obesity by disrupting lipid storage and metabolic
mechanisms and promotion of adipocyte hyperplasia [36, 37].
As evidenced by the above-discussed findings, pollution has diverse and bodywide effects on human health, thus increasing the risk of disease. Therefore,
identifying what makes an individual more at risk and understanding how lifestyle
choices influence pollutant-toxicity is of utmost importance.
1.1.2 Polychlorinated Biphenyls- An Overview
Polychlorinated Biphenyls, or PCBs are a group of synthetic organic
chemicals comprised of carbon, hydrogen, and chlorine atoms. There are over
200 different congeners of PCBs, with their differences being the number and
location of the chlorine atoms [2]. Due to their thermally stable and lipophilic
nature, PCBs were utilized extensively as lubricants and coolants in electrical
equipment and also in industrial products such as pigments and plasticizers.
PCBs production was banned in 1979 due to the observed environmental
persistence and potential human health effects, however because of their high
resistance to degradation, they still are present in the environment [2]. PCBs
biomagnify along the food chain and thus pose a risk for human exposure
through consumption of contaminated foods. The highest contaminated food
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substances include fish such as catfish, salmon, and carp, as well as other
animal products including meat and dairy. There is increasing evidence that
PCB exposure is associated with adverse health consequences [38]. Some of
the most toxic PCB congeners include the dioxin-like PCBs. These PCBs act
similarly to the compound tetrachlorodibenzodioxin (TCDD), through strong
binding of the aryl hydrocarbon receptor (AhR) which in turn triggers a cascade
of events resulting in the upregulation and uncoupling of cytochrome p450
Cyp1a1 resulting in production of reactive oxygen species [39]. This chronic
production of ROS causes systemic inflammation and subsequent inflammatory
health complications such as cardiovascular disease and diabetes. Evidence of
the effects of PCBs on specific organ systems was discussed in a prior section.
There is also evidence that PCBs can act through specific molecular
mechanisms such as epigenetic regulation and microRNA alterations. For
example, it has been demonstrated that exposure to PCB 126, a coplanar dioxinlike PCB, induces inflammation in endothelial cells through epigenetic regulation
of the NF-kB p65 subunit [40]. It was also shown in human umbilical vein
endothelial cells that the PCB mixture, Aroclor 1260 alters the expression of
microRNAs that are associated with vascular diseases, indicating yet another
mechanism by which PCBs can induce inflammatory disease [41] Further
research is still needed to understand the diverse mechanisms by which PCBs
induce health complications and specifically how diet and preexisting disease
influence the toxicity of these pollutants.
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1.1.3 Factors Influencing Pollutant-Induced Disease Risk
One major question to be addressed is why certain people are more
susceptible to pollutant-associated diseases? It has been demonstrated that
compromised health or sub-optimal lifestyles, may exacerbate the toxicity of
environmental pollutants. For example, it has been shown that pollutant toxicity is
worsened in animal models with non-alcoholic fatty liver disease (NAFLD) [42].
This illustrates the idea that individuals in poor health or with underlying disease
conditions may be more susceptible to environmental insult or other chemical or
non-chemical stressors. Additionally, it is now appreciated that events occurring
during pregnancy can play a significant role in the future health and disease risk
of the offspring [43]. It has been documented that the offspring of mothers
exposed to environmental pollutants during pregnancy exhibit effects that may be
detrimental and persist into adulthood [44, 45]. For example, particulate matter
exposure throughout pregnancy was observed to be associated with an
increased fetal C-reactive protein (CRP) level upon delivery, indicating that
prenatal pollution exposure may increase fetal inflammatory responses and thus
potentially alter long-term health outcomes [46]. Moreover, data from a
longitudinal birth cohort study revealed an association between prenatal
exposure to dichlorodiphenyltrichloroethane (DDT) and hypertension later in life,
further indicating the long-term negative effects of early-life pollutant exposure
[47]. Aside from compromised health and prenatal exposures, some individuals
may be susceptible to disease development associated with environmental
insults due to genetic predisposition to these non-communicable diseases. For
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example, certain genetic polymorphisms in oxidative stress genes and
inflammatory genes have been demonstrated to influence the respiratory effects
and susceptibility to air pollution [48].
1.2

Nutritional Modulation of Disease Risk and Pollutant Toxicity

As discussed above, the risk of pollutant-induced toxicity may be increased by
underlying diseases, prenatal exposures, and genetic predispositions. Because
certain unhealthy lifestyle choices can predispose an individual to disease, it can
be expected that this may allow for greater pollutant induced toxicity. Thus,
finding ways to achieve a healthy lifestyle and therefore reduce disease risk are
significant and highly important.
Recent evidence has shown that while genetics do play a role in disease risk,
it may be smaller than once thought. In a recent study published by Khera et al.
[49] it was observed that in participants with a high genetic risk of coronary artery
disease, those living a “favorable lifestyle” (i.e. no obesity, no smoking, regular
physical activity, and a healthy diet) had approximately a 50% lower relative risk
of coronary artery disease compared to those living an “unfavorable lifestyle”
[49]. These findings demonstrate just how influential our lifestyle choices are on
overall disease risk independent of genetic risk. For individuals looking to
achieve “favorable lifestyle” choices, a logical place to start is examination of
dietary habits. Because nutrition is such a critical aspect of life with food being a
fundamental component for survival, understanding how nutrition affects our
health is essential. Research has established that certain nutrition practices can
worsen health outcomes while others can provide benefits. This is well
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evidenced with the present global obesity epidemic, which has been attributed to
a reliance on processed, high fat, and nutrient poor foods that contribute to
excess energy intake relative to actual nutrient requirements [50]. While body fat
gain is the first visible complication of this chronic positive energy balance, the
internal inflammatory processes and metabolic complications elicited pose a
greater threat to overall well-being. These less visible metabolic complications
can even occur prior to any weight gain. For example, consumption of high fat
diets, with greater proportions of saturated, trans, and omega-6 fatty acids (e.g.,
linoleic acid) can increase inflammatory processes rapidly and thus long-term
cardiovascular disease risks [51, 52]. Additionally, research examining the
effects of consumption of processed meats has become a source of great
interest and controversy in the field of nutrition. As defined by the American
Institute for Cancer Research, processed meats are “meats preserved by
smoking, curing or salting, or addition of chemical preservatives”. Interestingly, a
meta-analysis conducted by Micha et al [53] revealed that a single serving per
day of processed meat was associated with a 42% increase in risk of coronary
heart disease and a 19% higher risk of diabetes mellitus [53].
On the other hand, it is well appreciated that many chronic diseases, such as
cardiovascular disease and type 2 diabetes, can be prevented or attenuated with
healthful dietary practices. This includes diets similar to that of the
Mediterranean diet, rich in omega-3 fatty acids, fruits, vegetables, and whole
grains [54, 55]. These dietary components, which are rich in antioxidant and antiinflammatory compounds (e.g., phytochemicals and polyphenols), may reduce or
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prevent the proinflammatory events associated with chronic metabolic diseases
[54, 55]. Additionally, there is also evidence that consumption of polyphenolic
compounds such as resveratrol, tea polyphenols, and curcumin can protect
against inflammation and chronic disease through alterations in proinflammatory
gene expression both directly and through epigenetic modifications.[56] For
example, curcumin, a principle component of the spice turmeric, has been
demonstrated to suppress or inhibit the expression of tumor necrosis factor-a
(TNF-α) as well as cyclooxygenase 2 (COX-2), the target of nonsteroidal antiinflammatory drugs (NSAIDs) [57, 58]. Additionally, the consumption of table
grapes, rich in polyphenolic compounds including resveratrol and anthocyanins,
have been shown to attenuate systemic inflammatory responses, hepatic
lipogenesis, and adiposity in mice fed a high fat diet [59]. Thus, dietary choices
are very powerful, and when chosen appropriately can vastly influence the
development of numerous metabolic diseases.
The underlying denominator of non-communicable diseases, such as those
observed from pollutant exposure, is oxidative stress and inflammation [60]. An
inflammatory process usually precedes other health effects, and thus it is a
critical step to understand and identify means to protect against inflammation.
Similar to the way in which nutrition can contribute to or protect from noncommunicable diseases, nutrition can also modulate the toxicity of environmental
pollutants, thereby altering overall disease risk.
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1.2.1 Poor Nutrition Can Exacerbate Pollutant Toxicity
It has been established that certain unhealthy nutrition practices can
actually worsen the toxicity of pollutant exposure. The overconsumption of
processed and refined foods contributes to diets high in inflammatory fatty acids,
which not only exacerbate diet-induced metabolic complications, but also
pollutant-associated inflammatory processes [61, 62]. These high-fat, processed
foods are also low in protective bioactive nutrients, thus leading to increased
oxidative stress and inflammation. Additional stressors, such as environmental
insults, added to this may result in a greater inflammatory response, which could
be due to the fact that the mechanisms of pollutant-induced toxicity and dietaryinduced inflammatory responses are similar [62]. This detrimental interplay of
nutrition and pollutants was illustrated comparing the effects of PCB exposure in
mice fed corn oil (high in linoleic acid) versus mice fed olive oil (high in oleic
acid). In corn oil fed mice, PCB exposure resulted in further increases in
expression of aortic vascular cell adhesion molecule 1 (VCAM-1). Importantly,
this observation was not observed in mice fed olive oil, indicating the selective
interaction of specific dietary fats with PCB inflammatory processes.[63] Others
have also observed this toxic interplay of pollutants and nutrition. For example, it
has been shown that high fat diets can exacerbate arsenic-associated liver
inflammation and fibrosis.[64] Additionally, diet-induced obesity and nonalcoholic fatty liver disease (NAFLD) are worsened in the presence of PCB 153,
further illustrating the detrimental interplay of poor nutrition and pollutant
exposure.[65]
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1.2.2 Healthful Nutrition Can Protect Against Pollutant Toxicity
As discussed above, individuals consuming a healthful diet already have a
lower risk of chronic inflammatory disease and thus may be less susceptible to
environmental insults and associated disease risks. This is important when
considering the observed increase in air pollution in many overpopulated parts of
the world and the link to risks of pulmonary and peripheral diseases. In fact,
biological and epidemiological evidence suggests that exposure to particulate
matter and related components of air pollution can contribute to oxidative stress
and inflammation, suggesting that intake of diets enriched in antioxidant and antiinflammatory nutrients should be advised to down-regulate pulmonary disease
risks [66-68]. There is evidence that specific nutrients can actually reduce the
toxicity and health complications associated with pollutant exposure. Diets rich in
bioactive food components such as omega-3 fatty acids and polyphenols, contain
high levels of antioxidant and anti-inflammatory compounds that are capable of
blunting the toxic and inflammatory effects of pollutant exposure [69].
Resveratrol, a polyphenol found abundantly in grapes, berries, and other plants,
has been shown attenuate hepatic steatosis and oxidative stress in mice
exposed to 2,3,7,8- tetrachlorodibenzo-p-dioxin (TCDD)[70]. Furthermore,
resveratrol has also been documented to combat PCB-induced disruptions in
adipocyte glucose homeostasis, which may protect against the development of
type 2 diabetes associated with pollutant exposure [71]. Another phenolic
compound, epigallocatechin gallate (EGCG), found in green tea, is capable of
attenuating cardiovascular inflammation and toxicity associated with arsenic
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exposure [72]. In support of this, our lab has observed that consumption of
green tea can reduce oxidative and inflammatory responses associated with PCB
126 exposure through up-regulation of antioxidant enzymes [73]. Importantly,
EGCG exhibits epigenetic regulation of NF-κB target genes, reducing PCB 126
induced endothelial cell inflammation mechanisms [74].
1.2.3 Nutritional Practices to Reduce Pollutant Body Burden
In addition to combatting pollutant-induced inflammation and toxicity
directly, there is evidence that certain nutritional components can actually aid in
reducing overall body burden of pollutants. Interestingly, it has been observed
that individuals consuming vegetarian or vegan diets exhibit trends towards lower
body burden of organochloride compounds [75]. These diets tend to be high in
polyphenols and antioxidant compounds due to their plant-based focus, and thus
it is possible that specific bioactive and plant-derived compounds may be
promoting greater excretion of pollutants. However, these associations need to
be further explored to determine if this is indeed the case. Because nutrition and
pollutants often interact with and alter similar mechanistic pathways, it is possible
that nutritional targeting of some of these pathways may be able to modulate
pollutant metabolism and excretion. One example of the overlap in nutritional and
pollutant interactions can be observed between arsenic and folate. For the body
to facilitate excretion of arsenic, it must undergo methylation, with Sadenosylmethionine (SAM) functioning as the methyl donor. Interestingly,
synthesis of SAM relies on a one-carbon metabolism that is folate-dependent
[76]. Therefore, supplementation with folate may enhance the methylation and
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subsequent excretion of arsenic. Indeed, Peters et al. recently observed that 12
and 24-week supplementations of 800μg/day of folic acid significantly reduced
blood arsenic concentration in an arsenic-exposed Bangladeshi population [76].
This finding is especially important due to the prevalence of chronic arsenic
exposure worldwide and supports the importance of fostering a better
understanding of the metabolism and excretion pathways of pollutants as
potential targets of intervention. In addition to nutritional modulation of molecular
mechanisms to enhance pollutant excretion, direct disruption or binding of these
pollutants via the enterohepatic circulation may also provide a means of
intervention to reduce body burden. For example, during this process, these
pollutants become exposed to the intestinal environment, thus providing an
avenue for potential dietary intervention. Indeed, it has been observed that
consumption of the dietary fat substitute, Olestra, a sucrose polyester which can
enhance the excretion rate of PCBs and hexachlorobenzene in mice and also in
highly exposed individuals [77-79]. This enhanced excretion is believed to be
through interference with the enterohepatic circulation of these pollutants.
Because of these findings, there is the potential that other nutritional components
may act similarly and be able to bind and increase pollutant excretion and
ultimately reduce the body burden of certain pollutants.
The levels of environmental pollution are on the rise worldwide, especially in
densely populated areas including China and India. Environmental pollution
impacts virtually every aspect of the human body, including the pulmonary and
gastrointestinal systems, liver, vasculature, and other peripheral tissues such as
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the adipose tissue. The diverse and detrimental impacts that pollutant exposure
has on these systems contribute to the increasing occurrence of chronic
inflammatory conditions observed worldwide. While efforts to reduce and
remediate pollution are underway, means of immediate protection at an individual
level is of upmost importance. Nutrition can have a drastic impact on the
development of or protection against non-communicable diseases, such as those
associated with pollutant exposure. There is increasing evidence of the
protective mechanisms of healthful nutrition on pollutant toxicity, specifically
regarding components of the Mediterranean diet (i.e. omega-3 fatty acids and
anti-inflammatory polyphenols), suggesting a means by which individuals may be
able to control the development of pollutant-associated disease risks. Because
nutrition is such a critical aspect of daily life, it is important to continue to foster a
better understanding of the ways in which the foods we consume can impact the
toxicity of environmental pollutants. Positive lifestyle changes such as healthful
nutrition (e.g., diets high in phytochemicals or polyphenols) may provide the most
sensible means to develop primary prevention strategies of diseases associated
with many environmental toxic insults.
1.3

The Gut Microbiome and Effects on Host Health
The term gut microbiota refers to the complete population of microorganisms

colonizing the intestines, and as current knowledge stands, is comprised of over
1000 species of bacteria [80]. The gut microbiome has been defined using
parameters including diversity, richness, and even distribution of microbial
communities. To classify these parameters, 16S rRNA gene sequencing or more

18

global scale metagenomic analyses are often implemented to compare bacterial
populations most commonly from stool samples, but also from intestinal biopsies
[81].
Over recent years, interest has grown significantly on understanding the ways
in which gut microbiota influence overall host health. Importantly, the gut
microbiome has been associated with numerous diseases and health conditions
including inflammatory bowel diseases, neurological illnesses, and metabolic
diseases [80]. Currently, the scientific community defines a “healthy” gut
microbiome as one with greater richness and bacterial diversity, as a reduced
bacterial diversity is often observed in obesity, diabetes, and other diseases [80].
Within the intestinal environment there are five main phyla of bacteria:
Bacteroidetes, Firmicutes, Actinobacteria, Proteobacteria, and Verrucomicrobia
[80]. It has been observed that in situations of obesity and chronic inflammatory
diseases, the ratio of Firmicutes to Bacteroidetes is increased and that this ratio
may not only be a result of these conditions but may actually be causal [80].
Studies using fecal microbiota transplantation (FMT) have been instrumental in
the scientific communities understanding of how the gut microbiome impacts
overall host health. For example, it has been demonstrated that performing FMT
from mice that were obese into lean mice lead to a significant increase in weight
gain in the mice receiving the obese microbiota [82]. Importantly, the reverse
has also been demonstrated in obese mice transplanted with lean mice
microbiota. Upon transplantation, the obese mice lost weight and had
improvements markers of glucose intolerance. While these experimental
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observations have been made, it is important to understand the mechanisms that
drive these findings. Therefore, current microbiota research focuses on
identifying core microbial species or genera that exert specific functions that may
aid in metabolism, contribute to immunity, reduce inflammation, or function in
communication with other organs (e.g. gut-brain axis). For example,
Bifidobacterium, Lactobacillus, Bacteroides, Eubacterium, Rosburia, and
Clostridium clusters IVa and XIVa have been associated with optimal
gastrointestinal functions and overall health in humans [83]. However, it is
important to note that these classifications are still very broad and thus making
generalizations at this level of taxonomy may not be most appropriate.
1.3.1 Microbial Metabolite Production
The primary end products of bacterial saccharolytic fermentation of nondigestible carbohydrates are short chain fatty acids (SCFAs). These SCFA are
formed when carbohydrates escape digestion and absorption in the small
intestine and thus persist into more distal regions of the digestive tract where
they are metabolized by the residing gut microbiota [84]. The primary SCFA
formed by bacterial fermentation are acetate, propionate, butyrate, and formate.
Lactate is also produced by several bacterial groups including lactic acid
bacteria, Bifidobacteria, and Proteobacteria, primarily from rapid fermenting nondigestible carbohydrates [85]. In addition to non-digestible carbohydrates, amino
acids may also be fermented and contribute to SCFA production, although this is
to a much smaller degree [84]. Through advanced metagenomic analyses,
characterization of specific bacterial species responsible for SCFA production
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has been made possible. While acetate is a common metabolite for most
bacterial species, lactate, propionate, and butyrate have been demonstrated to
be more specific with regards to both bacterial species and substrate [86]. Within
the the human microbiome, it has been demonstrated that a few species seem to
be main contributors to butyrate production, including Eubacterium rectale,
Eubacterium hallii, Faecalibacterium prausnitzii, and Ruminococcus bromii [87].
Furthermore, Akkermansia muciniphila, a mucin degrading bacterium has been
identified as a large contributor to propionate production [88]. This bacterium has
garnered much attention in the scientific community due to it being linked with
improved intestinal health and metabolic parameters in type 2 diabetic and obese
subjects, but there is still some debate on solely classifying this bacterium as
beneficial [88]. Nevertheless, A. muciniphila has been demonstrated to attenuate
the high fat-induced endotoxemia that occurs as a result of an impaired intestinal
barrier [89]. These protective effects on the intestinal barrier have also been
demonstrated in vitro, where it was shown that this bacterium binds to the
extracellular matrix protein laminin and strengthens the enterocyte monocyte
layer [90]. While it still remains unknown, there is potential that some of these
effects mediated by A. muciniphila are resultant of SCFA production. These
discussed specific bacterial species noted for SCFA production is by no means
exhaustive but demonstrates how metagenomic analysis has allowed the
functional characterization of certain bacterial species residing in the human
intestinal environment.
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SCFAs exert effects locally within the intestine and systemically and serve a
variety of purposes [91]. For example, butyrate serves as a preferential energy
source for the colonic epithelial cells, facilitating the maintenance of an
impermeable intestinal barrier through regulation of tight junction proteins such
as ZO-1, occludins, and claudins [91]. A strong intestinal barrier is critical for
preventing leakage of bacteria and toxins into systemic circulation, which can
contribute to chronic inflammatory responses that can influence the development
of disease [91, 92]. Additionally, SCFA concentrations are sensed by specific Gprotein coupled receptors (GPRs), GPR41 and GPR43, which are involved in
numerous systemic processes including the regulation of glucose and lipid
metabolism [91].
Another group of microbial metabolites that have been recently studied are
involve the compound L-tryptophan. L-tryptophan and its metabolites have been
demonstrated to be involved in gut immune function and also play a role in
several immune diseases [93]. Endogenous tryptophan metabolism is conducted
through two main pathways: the kynurenine pathway and the serotonin pathway,
which occur primarily in the liver [93]. Interestingly, the gut microbiota can utilize
tryptophan, limiting the availability of this compound to host tissues. It has been
estimated that the gut microbiota can metabolize 4-6% of dietary tryptophan,
resulting in the production of several compounds such as indole, indicant,
tryptamine, and skatole, as well as other indole acid derivatives [93]. The
understanding of which microbes possess the enzymes to metabolize tryptophan
is currently limited, however it is known that members of Firmicutes including
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Clostridium sporogenes and Ruminococcus gnavus are capable of producing
tryptamine and skatole can be produced from indole acetic acid by bacteria
belonging to the genera Lactobacillus, Clostridium, and Bacteroidetes [93].
Several other bacteria undoubtedly possess the capabilities to produce
tryptophan metabolites and as technology and understanding of the gut microbial
field progresses, the characterization of these microbes can be anticipated.
Studies have demonstrated that these microbial-derived tryptophan metabolites
can exert effects on host health, specifically through actions as ligands of the aryl
hydrocarbon receptor (AhR) [94-96]. AhR is critical to maintenance of intestinal
immunity and it has been demonstrated that excessive degradation of AhR
ligands can induce detrimental effects on immune homeostasis [97]. It has been
shown that during acute colitis, dietary tryptophan can alleviate colitis symptoms
in a DSS-inducible intestinal injury mouse model and that these effects are due
to microbial metabolites of tryptophan, not the parent compound [95]. A diet
containing high amounts of tryptophan can actually increase AhR mRNA
expression and the microbial metabolites that activate AhR result in the increase
in colonic expression of IL-22 [98]. Recently IL-22 has gotten a lot of attention
due to its discovered involvement in the maintenance of gut barrier function and
immune function in the intestine [99]. Furthermore IL-22 has also been shown to
play a role in anti-bacterial immunity, increasing clearance of specific pathogenic
bacteria, further supporting the therapeutic potential of diets rich in tryptophan
[100]. While research on this topic has progressed significantly over the past few
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years, there still is much research needed to investigate the potential other roles
that microbial-derived tryptophan metabolites play in gut and host health.
Some bacterial metabolites can also be detrimental and potentially contribute
to disease risk. The bacterial derived metabolite trimethylamine n-oxide (TMAO)
has recently been linked to coronary artery disease in the human population
[101]. TMAO is formed from quaternary nitrogen containing compounds such as
dietary choline, phosphatidylcholine, and carnitine. When ingested, these dietary
compounds are metabolized by the gut microbiota to generate trimethylamine
(TMA) and subsequently the liver enzyme flavin-containing monooxygenase 3
(FMO3) oxidizes it to form TMAO [101]. Evidence has shown that there are
several bacterial families involved in the production of TMA/TMAO. In human
and preclinical models, Deferribacteraceae, Prevotellaceae, Enterobacteriaceae,
and Anaeroplasmataceae have been demonstrated to contribute to the formation
of TMA [102]. Furthermore, in vitro, several species have been identified as TMA
producers including Anaerococcus hydrogenalis, Clostridium sporogenes, C.
hathewayi, Escherichia fergusonii, and others [103, 104]. Circulating levels of
TMAO have been associated with numerous deleterious disease states, from
cardiovascular disease, to chronic kidney disease, to type 2 diabetes [102].
Despite these findings, the debate still remains whether or not TMAO itself is
contributing to disease progression or if it is solely a biomarker that is a result of
a different diseae mechanism [105]. Additionally, recent research utilizing gut
microbial modulation to attempt to reduce circulating TMAO levels have been
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ineffective and inconclusive [106]. Due to these inconsistencies and debates,
there is a great need for more research in this area.
1.3.2 Modulation of the Gut Microbiome
The gut microbiome can be affected by to numerous factors, perhaps the
most notable being dietary habits. Diet has been demonstrated to rapidly and
consistently exert changes on gut microbiota, with some of these alterations
occurring within hours of dietary changes [107]. Studies examining the impacts
of dietary components on the gut microbiota have focused mostly on high fat
diets and high fiber diets, specifically looking at high fat diets as detrimental and
high fiber diets as beneficial for gut health and host outcomes. The evidence
behind each of these foci is discussed below.
High fat diets (HFD) have been consistently shown to negatively impact gut
microbial populations [108]. Generally, it has been shown that HFD consumption
can lead to a decrease in Bacteroidetes and increase in Firmicutes, which has
been associated with numerous chronic disease states [108]. One of the
mechanisms linking the consumption of a HFD to chronic disease is
hypothesized to be disruptions in gut permeability and increases in intestinal
inflammation [108]. For example, HFDs have been shown to reduce intestinal
tight junction proteins, which can increase bacterial translocation, elevate
circulating levels lipopolysaccharide (LPS) and contribute to inflammatory
outcomes [109]. Furthermore, HFDs have been shown to increase inflammatory
mediators within the small and large intestine of conventionally raised mice, but
not germ-free mice, indicating an involvement of the microbiota in HFD-induced
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inflammatory response [110]. It is important to note that high fat diets are often
low in dietary fiber, which is known to be a positive modulator of the microbiota.
Importantly, the detrimental impacts of a HFD on gut microbiota is not conclusive.
For example, gut microbiota research on the ketogenic diet, which focuses on
very high fat and low carbohydrate consumption, has shown to actually be
beneficial for microbial populations [111]. For example, it was shown that
ketogenic diet-fed mice had increased abundance of Akkermansia muciniphila
and Lactobacillus and reduced levels of supposed pro-inflammatory taxa such as
Dulsufovibrio [112]. Due to these inconsistencies in the literature regarding high
fat diets and effects on the gut microbiota, more research is needed to elucidate
the specific effects of HFD on microbiota and health outcomes in a variety of
populations.
Diets high in fiber have been consistently demonstrated to modulate the
microbiota. High fiber diets are well understood to be beneficial for host health,
specifically in regard to cardiovascular disease and diabetes prevention [113].
Previously, it was believed that these beneficial effects were solely mediated
through regulation of cholesterol levels and glucose homeostasis [113].
However, as understanding of the gut microbiota has increased, new research
has discovered that high fiber-induced modulation of the gut microbiota may play
a role in these previously observed effects [114-116]. One mechanism behind
the beneficial effects of diets high in fiber is increases in short chain fatty acid
(SCFA) production. Certain fibers are highly fermentable, meaning that they are
metabolized by the gut microbiota to produce metabolites, primarily SCFA, that
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can then be absorbed by the host. As discussed previously, SCFA have diverse
impacts both locally within the gut and systemically as metabolic substrates as
well as through ligand binding to specific receptors (e.g. GPR41 and GPR43)
[85]. Another mechanism by which high fiber diets may contribute to host health
is through immune modulation [117]. For example, it was recently shown that
fiber consumption protects against diet-induced obesity and systemic
inflammation through restoration of interleukin-22 (IL-22), which functions in
restoration of enterocyte function and fortification of the intestinal barrier [116].
These observations of fiber-induced beneficial effects involving SCFA and
immune modulation have been observed with highly fermentable fibers (e.g.
inulin), while research examining minimally fermented fibers (e.g. cellulose) has
not shown strong effects [118]. The fibers that are highly fermentable are termed
prebiotics, and is discussed extensively in later sections.
More recently, great interest has developed into specific modulation of the
microbiota with the intention to benefit gut and host health. This can be achieved
through use of probiotics, prebiotics, and synbiotics. Probiotics are defined as
actual live bacteria that when administered in adequate amounts, confer a health
benefit on the host [119]. In preclinical and clinical trials, the use of probiotics to
improve conditions including inflammatory bowel diseases, neurological
conditions, and diabetes have showed some promise [120, 121]. Unfortunately,
the benefits of probiotic supplementation do not always seem to translate to
healthy individuals, indicating that there may be only specific populations that can
benefit from probiotic use [122]. One common downfall of probiotic
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supplementations is that supplements in general are not regulated by the Food
and Drug Administration (FDA), which calls into question the quality, purity, and
actual bacterial content of probiotic supplements [119]. Another issue with
consumption of probiotics involves the potential side effects of gastrointestinal
upset and bloating, which varies between individuals and ultimately counteracts
the goal of these supplements as therapeutic agents [123]. There clearly needs
to be more research into the therapeutic potential and uses of probiotic
supplements, specifically focusing on the mechanistic roles of specific bacterial
species. Prebiotics will be discussed in detail in the following section.

1.4

Prebiotics: An Overview
The term prebiotic is defined as “a selectively fermented ingredient that allows

specific changes both in the composition and/or activity in the gastrointestinal
microbiota that confers benefits upon host well-being and health” [124]. The
most well-known group of prebiotics are dietary fibers, however other dietary
components may also fit this definition, seeing that they satisfy the functional
criteria. Currently, the literature shows that all prebiotics are fiber, however not
all fibers are prebiotic. It is recommended that humans consume at least 28g
and 35g of fiber per day for females and males, respectively [125]. However, in
the U.S., less than 3% of all Americans are meeting these recommended intakes
[125]. Prebiotics that have been documented in the literature as having
functional properties include inulin, fructooligosaccharides (FOS),
galactooligosaccharides (GOS), some disaccharides, and some nonstarch
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polysaccharides [126]. Prebiotics undergo microbial fermentation in the colon
yielding SCFAs, of which up to 95% are absorbed in the colon and therefore may
modulate host metabolic and inflammatory responses [126]. Consumption of a
diet rich in prebiotics is capable of reversing dysbiosis and attenuating
associated inflammatory conditions. It has been documented that prebiotic
consumption may reduce the risk of cardiovascular disease and diabetes,
primarily through the actions of the SCFAs discussed above [126]. Further
research is still needed to understand the diverse role of prebiotic consumption
on gut microbial composition, SCFA production, and associated host-responses.
As with probiotics, one complication with consumption of prebiotics is the
potential for gastrointestinal discomfort, especially in individuals that may have a
microbial composition unable to fully ferment the prebiotic [127]. As the literature
regarding the efficacy and health benefits of both prebiotics and probiotics
expands, a movement towards personalized recommendations of dietary and
bacterial supplemental protocols can be anticipated, much like the current
movement in the medical and nutrition field.
1.4.1 Inulin
Understanding the action and benefits of specific prebiotics is necessary to
better elucidate the manipulability of the gut microbiota and how this influences
host health. The prebiotic inulin is an inulin type fructan (ITF) containing linear
chains of fructosyl groups that are linked by (2-1) glycosidic bonds and
terminated with an -D(1-2)-glucopyranoside ring group on the reducing end
[128]. The chain length of inulin varies from having two to more than 100
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fructose units, which results in differences in fermentation by gut microbiota.
ITFs include inulin, oligofructose, fructooligosacchardies (FOS), and bifidogenic
oligo- or polysaccharide chains [129]. The latter compounds are smaller in size
and thus, have a smaller degree of polymerization (DP). Inulin itself has been
minimally processed so has a DP greater than 10 while the aforementioned
molecules have a DP less than 10. Notably, the greater the DP, the greater
effects will be in the distal colon with a smaller DP having more effect towards
the proximal colon [129]. One of the most common forms of inulin that is
available in food products or supplements is derived from chicory root, but inulin
is also found in garlic, onions, and other vegetables. Inulin is one of the most
studied prebiotics and its consumption has been associated with a host of health
benefits ranging from improved gastrointestinal function, improved glucose
control, and improvements in energy metabolism [129-131]. Specifically,
administration on inulin has been demonstrated to reduce adiposity and
parameters associated with metabolic syndrome [132, 133]. The mechanisms
behind the beneficial actions of inulin are believed to include alterations in
gastrointestinal peptide and short chain fatty acid production, regulation of the
immune system, and modulation of lipid metabolism. While humans lack the
enzymes to metabolize and garner energy from inulin, the production of SCFA is
thought to contribute to approximately 1 kilocalorie per gram of fiber for the host
[118]. Furthermore, it was recently shown that inulin supplementation protected
against diet-induced obesity through improving gut microbiota populations and
restoring enterocyte function through effects on IL-22 [116]. These observed
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mechanisms are also dependent and linked to alterations in gut microbiota.
Inulin is known to have strong stimulatory prebiotic activity amongst specific
bacterial groups including Bifidiobacterium spp., Anaerostipes spp., as well as
Lactobacillus gasseri, and Faecalibacterium prausnitzii. [134] The latter two
bacteria are of interest and importance due to their known production of butyrate
and potential therapeutic contribution to host health. Furthermore, it was recently
observed that inulin administration resulted in reduction in Bilophila, a member of
the Desulfovibrionacaeae family [134, 135]. This is important because
Desulfovibrionacaeae are known sulfate-reducing bacteria that produce
hydrogen sulfide (H2S), a genotoxic gas that can hamper intestinal health. As
such, reductions in Bilophila spp. following inulin administration has been
associated with improved gut barrier function [134]. These observations offer
another gut microbial dependent mechanistic insight into the health benefits of
inulin consumption.
With regards to overall human health and disease outcomes, studies have
examined the effects of inulin consumption on outcomes related to diabetes and
cardiovascular diseases. For example, in prediabetic patients, inulin
supplementation aided in weight reduction and reduced intrahepatocellular and
intramyocellular lipid content, which the authors suggest contributed to observed
improvements in glucose homeostasis [136]. Inulin also has potential
applications in the prevention of cardiovascular disease with several studies
finding an improvement in blood lipids and lipoproteins with inulin
supplementation. Importantly, in a meta-analysis, it was found that the most
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profound effect of consumption of inulin-type fructans was on lowering of low
density lipoprotein (LDL) levels, an effect well evidenced to lower the risk of
adverse cardiovascular events [137]. Because it is still unknown if these
discussed clinical findings are solely gut-microbial dependent, more research is
needed to elucidate the protective mechanism of inulin on diabetic and
cardiovascular outcomes.
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1.5

Scope of Dissertation

1.5.1 Aims of dissertation
The overall objective of this project is to elucidate the effects of PCB 126 on
gut microbial homeostasis and cardiometabolic disease and how nutritive
measures may be able to protect against the effects of pollutant exposure. PCB
126 was chosen as the model pollutant in this study due to its known effects on
human health as well as a substantial quantifiable prevalence in human
samples[138].
Our central hypothesis is that exposure to PCB 126 disrupts host health and
increases the risk for cardiometabolic disease in a gut-microbial dependent
manner and that prebiotic (i.e. inulin) consumption will be able to attenuate these
effects and reduce the risk of disease. As such, we will test our central
hypothesis by these three specific aims:
Specific Aim 1. Test the hypothesis that PCB 126 directly disrupts gut microbial
fermentation and viability.
Specific Aim 2. Test the hypothesis that PCB 126 negatively alters murine gut
microbial populations and/or gut health, exacerbating inflammatory and metabolic
complications involved in cardiometabolic disease.
Specific Aim 3. Test the hypothesis that consumption of the prebiotic inulin can
decrease PCB-induced disruption in gut microbial and metabolic homeostasis
and ultimately protect against cardiometabolic disease.
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Chapter 2

Environmental pollutant-mediated disruption of gut microbial
metabolism of the prebiotic inulin
Anaerobe: PMID: 30447394

Jessie B. Hoffman, Michael D. Flythe, Bernhard Hennig [139]
2.1

Synopsis
Exposure to environmental pollutants is associated with a greater risk for

metabolic diseases including cardiovascular disease. Pollutant exposure can
also alter gut microbial populations that may contribute to metabolic effects and
progression of inflammatory diseases. Short-chain fatty acids (SCFAs),
produced from gut fermentation of dietary carbohydrates, such as inulin, exert
numerous effects on host energy metabolism and are linked to a reduced risk of
diseases. The hypothesis was that exposure to dioxin-like pollutants modulate
gut microbial viability and/or fermentation processes. An inulin-utilizing isolate
was collected from murine feces, characterized and used in subsequent
experiments. Exposure to polychlorinated biphenyl, PCB 126 impeded bacterial
viability of the isolate at concentrations of 20 and 200 µM. PCB 126 exposure
also resulted in a significant loss of intracellular potassium following exposure,
indicating cell membrane disruption of the isolate. Furthermore, total fecal
microbe samples from mice were harvested, resuspended and incubated for 24
hours in anaerobic media containing inulin with or without PCB 126. HPLC
analysis of supernatants revealed that PCB 126 exposure reduced succinic acid
production, but increased propionate production, both of which can influence host
glucose and lipid metabolism. Overall, the presented evidence supports the idea
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that pollutant exposure may contribute to alterations in host metabolism through
gut microbiota-dependent mechanisms, specifically through bacterial
fermentation processes or membrane disruption.

2.2

Introduction

Exposure to environmental pollutants can illicit numerous deleterious health
effects. Polychlorinated biphenyls are a class of persistent organic pollutants
that increase development of chronic inflammatory diseases such as diabetes
and atherosclerosis, primarily through inflammatory mechanisms [2]. Due to their
lipophilic nature, they accumulate in the adipose tissue of living organisms and
bioaccumulate along the food chain. Thus, one of the primary routes of human
exposure is through the ingestion of contaminated foods including fatty meats,
fish, and dairy [2]. This exposure route is unique in that it has the ability to
directly impact the gastrointestinal tract and gut microbiota.
The gut microbiota can be impacted by outside influences including diet and
environmental exposures [80]. Over the past decade, greater appreciation and
understanding has come about regarding the gut microbiota and its influence on
overall host health and wellbeing. The gut microbiota exerts impacts on
neurological, metabolic, and inflammatory bowel diseases, highlighting the
diverse and wide reaching impact of our intestinal bacterial residents [140].
Fermentation is an innate aspect of gut microbial metabolism and the metabolites
produced can have diverse impacts on host health. The primary end products of
bacterial saccharolytic fermentation of non-digestible carbohydrates are short
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chain fatty acids (SCFAs). These SCFA are formed when carbohydrates escape
digestion and absorption in the small intestine and thus persist into more distal
regions of the digestive tract where they are metabolized by the residing gut
microbiota [91]. The primary SCFA formed by bacterial fermentation are acetate,
propionate, and butyrate, although there are numerous other fermentation acids
produced. SCFA exert effects both locally, within the intestine, and systemically,
and they serve a variety of biological purposes [91]. For example, butyrate
serves as a preferential energy source for the colonic epithelial cells, facilitating
the maintenance of an intestinal barrier through regulation of tight junction
proteins such as ZO-1, occludins, and claudins [86, 91]. A strong intestinal
barrier is critical for preventing leakage of bacteria and toxins into the systemic
circulation, which may contribute to chronic inflammatory responses that can
influence the development of disease [91, 92]. Additionally, SCFA concentrations
are sensed by specific G-protein coupled receptors (GPRs), GPR41 and GPR43,
which are involved in numerous systemic processes including the regulation of
glucose and lipid metabolism [86, 91].
The prebiotic inulin is a polymer of fructans containing linear chains of fructosyl
groups that are linked by B(2-1) glycosidic bonds and terminated with an alpha
D(1-2)-glucopyranoside ring group on the reducing end [118]. The chain length
of inulin varies from having two to more than 100 fructose units, which results in
differences in fermentation by gut microbiota [118]. In preclinical and clinical
models, inulin has been demonstrated to have beneficial effects on several
disease states including cardiovascular disease and diabetes [129, 135, 141].
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Inulin is fermented by certain members of the gut microbial community to
produce short chain fatty acids including acetate, propionate, and butyrate, which
is believed to be one of the mechanisms of action in which inulin exerts host
health effects [130]. In the human nutrition community, inulin, is commonly
referred to as a dietary fiber based on its inability to be metabolized by
mammalian enzymes and thus is not absorbed by the human body [142]. Due to
the observed health effects of inulin consumption, it is commonly added to
numerous food products to increase the dietary fiber content while adding slight
non-caloric sweetness.
Our lab has demonstrated previously that PCB 126 exposure decreases gut
microbial diversity, reduces specific bacterial populations, and impacts overall
host metabolism in a mouse model [143]. However, little is known about the
mechanisms by which PCBs impact the gut microbiota and how this may
translate to effects for the host. Therefore, the objective of this study was to
examine the impacts of PCB 126 exposure on gut microbial viability and
fermentation utilizing the prebiotic inulin as a substrate.

2.3

Materials and Methods

2.3.1 Materials and Chemicals
Inulin from chicory was purchased from Sigma Aldrich (St. Louis, MO,
USA). 3,3’,4,4’,5-pentachlorobiphenyl (PCB 126) was obtained from
AccuStandard Inc. (New Haven, CT, USA).
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2.3.2 Animals and Fecal Collection
Male C56BL6/J mice were fed a standard chow diet ad libitum, housed at
22 C with 50% humidity, and exposed to a 12-h light/ 12-h dark cycle. When
fecal samples were needed for in vitro experiments, fresh fecal pellets were
collected from mice and immediately placed in a sterile microcentrifuge tube.
Samples were quickly transferred in an insulated container at 37 C for
immediate experiment setup to ensure bacterial viability. For fermentation
experiments, fecal cell suspensions were made from pooled samples of three
mice and repeated a total of three times. The University of Kentucky animal care
and use committee approved all animal procedures.

2.3.3 Media and Anaerobic Technique
Growth medium was prepared, and cultures were transferred using the
Hungate anaerobic method. Growth medium contained (per 1 L) 240 mg
KH2PO4, 240 mg K2HPO4, 480 mg NaCl, 480 mg (NH4)2SO4, 100 mg MgSO4
7H2O, 64 mg CaCl2 2H2O, and 600 mg cysteine hydrochloride [144]. Media was
adjusted to a pH of 6.7 by adding NaOH, autoclaved to remove O2, and cooled
under CO2, at which point 4.0 g Na2CO2 was added. Media was then
anaerobically transferred to Hungate tubes, capped with rubber stoppers and
aluminum seals, and autoclaved for sterilization. Inulin was prepared
anaerobically and added aseptically at a concentration of 4 g/L unless otherwise
indicated. Cultures were routinely transferred with anaerobic technique using a
tuberculin syringe and incubated at 37°C.
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2.3.4 Inulin-Fermenter Enumeration, Isolation, and Characterization
Fecal samples (175 mg) were placed in anaerobic chamber (Coy Labs,
Grass Lake, MI; 95% CO2, 5% H2), suspended in 1 mL dilution buffer (PBS), and
subjected to 10-fold serial dilution in dilution buffer using sterile anaerobic
techniques. Samples (200 µL) from the dilutions were plated on basal medium
agar (15 mg/mL) containing 4g/L of inulin for bacterial isolation. Dilution plates
were incubated in an anaerobic chamber for 72h at 37 C. Following incubation,
colonies were isolated and grown in liquid growth media (4 g/L inulin) at 37 C for
24-48h. Cultures were then characterized by Gram staining and light
microscopy. Phylogenetic identity was determined via 16S rRNA sequencing.
Genomic DNA was extracted (QiaAMP DNA Mini Stool Kit; Qiagen, CA, USA)
and amplified by PCR using PuReTaq Ready-to-Go PCR beads (GE
Healthcare, Buckinghamshire, United Kingdom) and universal 16S primers (10
pmol; Integrated DNA Technologies, Coralville, IA, USA; Forward-5'AGAGTTTGATCCTGGCTCAG-3', Reverse – 3'ACGGCTACCTTGTTACGACTT-5'). The PCR cycles were: denaturing (94 °C; 5
min), 35 cycles (94 °C, 0.5 min; 55 °C, 1 min; 72 °C, 1 min), and final extension
(72 °C; 5 min). PCR products were sequenced by the University of Kentucky,
sequencing core facility (Lexington, KY, USA) using an ABI 3730 DNA Analyzer
(Applied Biosystems, CT, USA). The closest phylogenetic relatives were
identified using a BLAST search of GenBank [145]. The 16S sequences were
aligned and a phylogenetic dendrogram was assembled using the NeighborJoining method in Geneious (version 10.2.5). The bacterial isolate was further
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characterized for substrate utilization using an API 20A kit (BioMeriux, Marcy
l'Etoile, France).

2.3.5 Growth Experiments
Growth experiments were conducted in growth media (9mL, pH 6.7) in
Hungate tubes. Stock solutions of PCB 126 were solubilized in DMSO and the
same amounts of DMSO as in PCB-treated cultures were added to control
cultures. The levels of DMSO in cultures was less than 0.05%. PCB 126 (0.02
µM) or control (DMSO) was added to growth media prior to inoculation with JB12
cultures. The dose of 0.2 µM was chosen as a level that has been documented a
in exposed human populations. Each tube was inoculated with (1% v/v) from
stationary phase (16 h) cultures and incubated at 37*C. Optical densities were
determined via spectrophotometry (600 nm) to quantify bacterial growth.
The effect of increasing concentrations of PCB 126 on the growth of the
inulin-fermenting isolate was conducted via broth dilution (10-fold increments).
Isolates were transferred in growth media (9 mL, pH 6.7) containing 4 g/L of
inulin that was prepared using sterile anaerobic technique. PCB 126 was added
to growth media via a Hamilton syringe in 10-fold dilutions (0.02, 0.2, 2, 20, 200
µM). Each tube was inoculated with a stationary phase from 16h cultures and
incubated at 37 C. Optical densities were recorded 24h after inoculation and the
degree to which growth was observed was documented. All growth experiments
were conducted in triplicate.
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2.3.6 Intracellular Potassium Quantification
Intracellular potassium was quantified using a method described in Flythe et.
al.2007 [146]. Growing cultures were energized with glucose for 25min, at which
point PCB 126 or vehicle control (DMSO) were introduced. Concentrations and
preparations of PCB 126 and DMSO were as described above. At each
timepoint, cells were separated from supernatant via centrifugation (13000g, 1
min) through silicon oil using a 50:50 mixture of Dexter Hysol 550 and 560. Cell
pellets were removed with dog nail trimmers, and subsequently digested in 3 N
HNO3 (25 C for 72h). Insoluble cell material was removed via centrifugation
(13,000g, 2 min) and the potassium concentrations were determined using flame
photometry (Cole-Parmer 2655-00 Digital Flame Analyzer; Cole-Parmer
Instruments, IL, USA).

2.3.7 Fecal Cell Suspensions
Fecal samples (175 mg) were placed in an anaerobic chamber and
suspended in 9mL of basal medium[144]. Samples were centrifuged (340g, 5
min) to remove major undigested material. Supernatants were collected and
centrifuged (25,000g, 10 min) to pellet bacteria. Bacterial pellets were
resuspended in 9mL of growth medium and split into 3 tubes each containing 2
mL of bacterial suspension. PCB 126 (0.02, 0.2 or 2µM final conc.) or vehicle
control (DMSO) and inulin (4 g/L or 10 g/L final conc.) were added to the
bacterial suspensions. The preparation of PCB 126 and DMSO were the same
as described above. The pH and optical density (OD; absorbance at 600 nm)
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were quantified to ensure normalization. Samples were incubated for 0h or 48h
at 37 C, centrifuged (21,000g, 2 min) to collect supernatant for fermentation end
product quantification, and frozen stored at -20 C until analysis.
2.3.8 Fermentation End Product Quantification
Fermentation end product quantification was conducted as discussed
previously.[144] Supernatant samples were thawed and clarified in a
microcentrifuge (21,000g, 2 min) for short-chain fatty acid (SCFA) quantifications.
SCFAs were quantified using as Summit HPLC (Dionex; CA, USA). Extracts
(100 µL) were injected into an anion-exchange column (Amine HP-87H; Bio-Rad,
Hercules, CA) at 50 C, separated isocratically with 5 mM sulfuric acid (0.4
mL/min flow rate), and subsequently detected via refractive index and UV
absorption at 210 nm.

2.3.9 Statistical Analyses
Each experiment was performed in triplicate. Data were input into
GraphPad Prism (GraphPad Software, Inc., La Jolla, CA) for statistical analyses
and graphing. Growth inhibition, intracellular potassium, and fermentation acid
data were analyzed by Student’s t-test to calculate comparisons of means
between treatment groups. All data are presented as means + SEM and results
were considered statistically significant with an observed p-value <0.05.
2.4

Results
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2.4.1 Identification of an inulin-fermenting isolate
An inulin fermenting microorganism (JB12) was isolated mouse feces.
The isolate formed smooth, white opaque colonies approximately 1mm in
diameter on basal medium agar with 4 g/L inulin. Culture purity was confirmed
through repeated isolation streak. Sequence homology (16S rRNA) revealed
that the closest characterized relative of JB12 was Acutalibacter muris (96%
identity), a member of the Ruminococcaceae (Figure 2.1). JB12 was Grampositive, and, unlike A. muris, it formed central endospores. In addition to inulin,
JB12 metabolized glucose, saccharose, maltose, salicin, xylose, cellobiose,
mannose, and trehalose (Table 2.1)[147-149].
2.4.2 Effect of PCB 126 on bacterial growth
To elucidate the effects of PCB 126 on an isolate JB12, experiments
examining growth effects were conducted. For growth curve experiments, PCB
126 (0.02 µM) or control (DMSO) was added to growth media (9 mL) and
subsequently inoculated with a stationary phase (16h culture; 1% v/v) of JB12
cultures. Cultures were incubated at 37*C and growth was quantified over time
via optical densities (600 nm). JB12 grew rapidly in the growth medium with
inulin as the substrate and reached an optical density of ~2.6 in 9h. (Figure 2.2).
PCB 126 exposure partially inhibited growth of JB12, reaching an optical density
of ~1.6 in 9h.
To examine the effects of PCB 126 dose on JB12 growth, increasing doses of
PCB 126 were added to tubes containing basal media which were subsequently
inoculated with a stationary phase (16h) culture of JB12 and incubated at 37°C
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for 24h. 24h after inoculation, growth was evaluated via optical density. We
observed a significant reduction of bacterial growth at the two highest PCB 126
concentrations (20 µM and 200 µM) compared to control (P<0.05) (Figure 2.3).
Apparent reduction in bacterial growth at lower PCB concentrations less than 20
µM were not significant.
2.4.3 Disruption of bacterial cell membrane by PCB 126
When cell suspensions of the inulin-fermenting isolate were energized with
glucose, they accumulated intracellular potassium. When PCB 126 was added
to the cell suspension, energized cells continuously lost intracellular potassium
while a control that received only vehicle continued to accumulate intracellular
potassium (Figure 2.4). Significantly lower levels of intracellular-potassium
observed at 35, 45, 55, and 65 minutes compared to vehicle control.

2.4.4 PCB 126-induced modulation of fermentation acid production from inulin
substrate
Fecal cell suspensions were grown and maintained using inulin as a substrate
(4g/L or 10g/L) and exposed to PCB 126 at varying doses or DMSO control for
48h. Examination of the fermentation acid production from inulin at 4g/L
revealed that the highest concentrations of PCB 126 (0.2 µM and 2 µM)
significantly reduced production of succinate (Figure 2.5). Additionally, PCB 126
exposure significantly increased propionate concentrations in the 2µM exposed
cells. The cells that were not exposed to PCB 126 produced 46 mM total
fermentation acids, including 11 mM propionate, 12 mM butyrate, and 21 mM
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acetate. To further understand the effects of PCB 126 on fermentation acid
production, we performed a second experiment in which the inulin substrate
concentration was increased to 10g/L. At this increased concentration of inulin,
PCB 126 exerted no significant effects on fermentation acid production at any of
the exposure levels (Figure 2.6).
2.5

Discussion
The objective of this study was to examine the impacts of PCB 126 exposure

on gut fermentation utilizing the prebiotic inulin as a substrate. Previous results
indicated that the dioxin-like PCB altered the population sizes of a variety of
phylogenetic groups in the hindgut when mice received the toxicant in vivo [143].
The current study follows up by mechanistically examining the effects of PCB
126 on bacteria isolated from murine feces. The effects on uncultivated hindgut
bacterial fermentation ex vivo are also shown. Bacterial fermentation is a key
metabolic process allowing bacteria to extract energy from compounds that the
host takes in [86, 91]. Products of fermentation of indigestible carbohydrates,
such as inulin, include various fermentation acids or short chain fatty acids.
SCFA are common, easily-quantifiable products of bacterial fermentation and
thus are a good measure to examine potential pollutant-induced effects [86, 91].
Inulin was chosen as the host-indigestible carbohydrate substrate due to its
increased popularity in the food and supplement industry as well as the strong
basis of scientific evidence linking inulin consumption to beneficial host health
outcomes [130, 150-152]. United States citizens ingest 1-4g of inulin-type
fructans per day, which can be anticipated to rise with increasing popularity[153].
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Administration of inulin has been demonstrated to reduce adiposity and
parameters associated with metabolic syndrome [129, 135, 152]. The
mechanisms behind the beneficial actions of inulin are believed to include
alterations in gastrointestinal peptide and short chain fatty acid production,
regulation of the immune system, and modulation of lipid metabolism [152]. For
example, Weitkunat et. al. found that gnotobiotic mice colonized with a human
microbiota and fed an inulin-enriched diet had significantly greater amounts of
acetate, propionate and butyrate in the cecum as well as elevated levels of
acetate and propionate in the plasma of the portal vein compared to mice fed
cellulose [154]. Inulin feeding also altered hepatic genes associated with
lipogenesis and fatty acid elongation, which was hypothesized to be due to the
differences in short chain fatty acid levels. These data highlight the fermentative
capability of inulin and the role that fermentation products (SCFA) play on overall
host health, making inulin a relevant substrate to study the effects of pollutant
exposure.
An inulin-utilizing microorganism was isolated from feces in order to examine
the inhibitory effects of PCB 126 at a physiological level. The isolate (JB12) was
most closely related to Acutalibacter muris which was previously isolated from
murine feces [149]. Isolate JB12 grew rapidly in the growth medium when inulin
was provided as the substrate, but growth slowed in an apparent stationary
phase in the presence of PCB 126 at 0.2 µM. However, the growth appeared to
be diauxic because greater optical densities were observed at 24h (Figure 3). At
24h, there was a dose-response inhibitory effect of PCB 126 on the culture.
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Diauxic, or biphasic, growth is not surprising because inulin is not truly a single
substrate. It is composed of oligofructose of different chain lengths, which are
fermented at different rates and to different extents [155]. When polymers of
different chain lengths are fermented as though they were different substrates,
classical diauxic growth could occur [156]. It was also observed that
concentrations greater than 20 µM of the polychlorinated biphenyl reduced the
growth of JB12. These results are consistent with the previous in vivo data that
showed PCB 126 exposure disrupted bacterial populations and decreased
bacterial diversity [143]. However, the antimicrobial mechanism of action of PCB
126 on gut bacteria was unknown. Previously, research was conducted on the
effects of PCBs and other environmental pollutants on soil microbes [157]. It has
been discussed that there is no convincing evidence that PCBs exert genotoxicity
in bacteria, such as Salmonella enterica [158]. Additionally, there is some
evidence that PCBs may be membrane active within specific soil microbial
populations [157]; therefore, we examined the effect of PCB 126 on the
intracellular potassium of isolate JB12. Potassium is the main intracellular cation
in bacterial cells and serves important roles such as acting as a cofactor for
certain enzymes [159]. Quantification of intracellular potassium is a method that
allows examination of potential membrane disruptions that that result in the
leakage or loss of this intracellular cation. We observed that upon exposure to
PCB 126, the bacterial cells rapidly lost potassium, which is consistent with a
loss of cell membrane integrity. This result indicates that bacterial cell
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membrane disruption is a potential antimicrobial mechanism of action by which
polychlorinated biphenyls could disrupt gut microbial communities.
To better understand how these findings may impact the gut microbiota as a
whole, we examined the effects of PCB 126 on fermentation acid production in a
fecal microbial cell suspension. PCB 126 addition (0.2 µM and 2 µM) to the fecal
cell suspension completely inhibited succinate production and increased
propionate production (2 µM). This is important for the host due because
succinate is a substrate in intestinal gluconeogenesis. Impaired intestinal
gluconeogenesis was shown to impact systemic glucose tolerance [160].
Furthermore, microbiota-derived succinate was shown to improve glucose and
insulin tolerance in wild-type mice [161]. It has been documented that PCB 126
disrupts glucose tolerance, yielding a diabetic phenotype in mouse models, thus
this new finding of microbial-derived succinate loss with PCB 126 may play a role
in this previously observed phenotype [162]. An increase in propionate was also
observed in the fecal cell suspensions exposed to PCB 126, which may have
implications in alterations in host hepatic metabolism. In support of this data,
previous in vivo evidence indicated an increase in propionate producers including
Clostridiales [163] and Akkermansia [88] in cecum samples of mice exposed to
PCB 126 [143]. Propionate can affect hepatic de novo lipogenesis as well as
lipolysis and in humans an increased level of propionate has been observed in
individuals with non-alcoholic fatty liver disease [164]. It is well documented that
exposure to dioxin-like pollutants increases hepatic lipid content and exacerbated
non-alcoholic fatty liver disease [42, 165]. Therefore, the effects observed on
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propionate production have the potential to contribute to these well-known
hepatic consequences of pollutant exposure.
The modulatory effects of PCB 126 on fermentation acid production were not
observed when the inulin concentration was increased to 10 g/L. This is not
surprising because all of the microorganisms in the gut microbiome were not
sensitive to PCB 126 at the concentrations tested. At higher inulin
concentrations, lactate was a major end product. Lactic acid production is
common when easily fermented carbohydrate is in excess. Many Firmicutes
(e.g. streptococci) and Proteobacteria (e.g. E. coli) possess a 1,6- fructose
bisphosphate (FBP)-dependent lactate dehydrogenase (LDH) [166]. Rapid
membrane transport of sugars leads to an increase in cellular FBP, which
triggers LDH and homolactic metabolism [166]. Abundant lactate production
regardless of PCB 126 suggests that one or more fructanolytic lactic acid
bacterial species were not sensitive to PCB 126. It is important to note that
increased lactate production from fructans fermentation is not always beneficial.
For example, in horses, excess lactate production and resultant drop in pH in the
hindgut can increase intestinal permeability and contribute to the development of
laminitis, resulting in required euthanasia [144]. Our present data do not warrant
a suggestion for excess consumption of inulin, but rather serves to highlight that
the bacterial populations that are able to grow at higher concentrations of inulin
are not sensitive to PCB 126. These data indicate that PCBs might be
selectively toxic to specific gut microbial populations.
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Although this present study is novel and adds to the growing body of literature
examining the impacts of pollutant exposure on gut microbial populations, there
are a few limitations that should be noted and addressed in subsequent studies.
First, the mechanistic aspects of this study focus on a single isolate and thus the
translatability of our findings to other microbial species is limited but should be
examined in future experiments. Additionally, It has been reported that serum
concentrations of PCBs can be found at approximately 3µM in exposed
individuals [167]. Due to the primary route of exposure (i.e. food consumption), it
could be expected then that the intestinal environment sees similar or higher
levels. Thus, the 0.02µM, 0.2µM and 2µM concentrations used for most
experiments in this manuscript are physiologically relevant, especially in heavily
exposed populations. However, the highest concentrations in utilized in the
inhibition experiment (Figure 3) are supraphysiological. Use of these higher
levels, while not found in human populations, is important to help characterize
and better understand the microbial impact of PCB 126. Furthermore, the
experiments conducted in the present study are representative of acute
exposures while humans often see more chronic exposures due to the primary
route of exposure of PCBs (i.e. food) and their participation in enterohepatic
circulation. Thus, gastrointestinal microbial populations are continually exposed
to these pollutants which could elicit a different and perhaps more detrimental
response over time. Finally, it appears that some microbiota are effected by
exposure to PCB 126 while others are not. This is the first study to show impacts
of a polychlorinated biphenyl compound on fermentation by gut microbiota. It
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remains to be seen if this interaction of the native gut microorganisms with an
environmental toxicant is beneficial to the host.
PCB 126 decreased the fermentative ability and viability of an inulinmetabolizing murine fecal bacterium. Potassium efflux indicated that the
mechanism of action was membrane perturbation. The fermentation of washed
fecal microorganisms were also impacted by PCB 126 ex vivo when the inulin
concentration was low. However, the toxicant was not inhibitory to fermentation
when the inulin concentration was greater. These results indicate that not all
species (e.g. the lactic acid bacteria that flourish under carbohydrate excess
conditions) were equally sensitive, a conclusion which is consistent with previous
results by our research group using culture-independent methods [13].
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Table 2.1. Substrate utilization profile of isolate JB12 and relatives

+ positive reaction; - negative reaction; (w) weakly; n.d. not determined [134,135,136]
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Figure 2.1. A phylogenetic dendrogram of isolate JB12 and close relatives

Figure 2.1. A phylogenetic dendrogram of isolate JB12 and close relatives.
Relationships were based on 16S rRNA sequences. The tree was constructed
using the neighbor-joining method in Geneious (version 10.2.5) and bootstrap
values are expressed as a percentage of 1000 replications. The scale
represents a 2% difference in nucleotide sequence.
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Figure 2.2. PCB 126 reduces growth of an inulin-fermenting isolate.

Figure 2.2. PCB 126 reduces growth of an inulin-fermenting isolate. A
growing culture of JB-12 was inoculated into media containing 4 g/L of inulin with
either PCB 126 (0.2 µM) or vehicle control (CTR; DMSO) and incubated at 37°C.
Optical density measures were conducted at time intervals to quantify growth.
Experiments were conducted in triplicate and representative data are shown.
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Figure 2.3. PCB 126 is an inhibitor to an inulin-utilizing bacteria

Figure 2.3. PCB 126 is an inhibitor to an inulin-utilizing bacteria. Growing
cultures of isolate JB12 were exposed to increasing concentrations of PCB 126
(0.02, 0.2, 2, 20, 200 µM) and optical density was quantified after 24 hours of
incubation (n=3). PCB 126 impeded bacterial growth at concentrations of 20 and
200 µM (p<0.05). All data are presented as means + SEM. *Statistically
different compared to 0 µM PCB 126 control (p<0.05; Student’s t-test).
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Figure 2.4. PCB 126 exposure decreases levels of intracellular potassium in
energized inulin-fermenting strain JB12

Figure 2.4. PCB 126 exposure decreases levels of intracellular potassium in
energized inulin-fermenting strain JB12. Growing cultures were energized
with glucose at time 0 and PCB126 and vehicle control (DMSO) were introduced
at 25m (n=3). Samples at each timepoint were subject to centrifugation to
remove insoluble cell material and potassium concentration was determined
using flame photometry. PCB 126 significantly reduced intracellular potassium
levels at 35, 45, 55, and 65 minutes compared to vehicle control. All data are
presented as means + SEM. * Significantly different compared to vehicle control
(DMSO) at specific timepoint (p<0.05; Student’s t-test)

56

Figure 2.5. PCB 126 treatment differentially modulates fermentative SCFA from
moderate concentrations of the dietary fiber inulin

Figure 2.5. PCB 126 treatment differentially modulates fermentative SCFA
from moderate concentrations of the dietary fiber inulin. Bacterial cell
suspensions were maintained on inulin substrate (4 g/L) and subsequently
exposed to PCB 126 (0.02 µM, 0.2 µM, 2 µM) or vehicle control (DMSO) for 48h
(n=3). HPLC was utilized to quantify fermentation acids in the media after
incubation. PCB 126 significantly reduced production of succinate at 0.2 µM and
2µM exposure concentrations and significantly increased propionate production
at the 2 µM concentration. All data are presented as means + SEM. *
Significantly different compared to vehicle control (DMSO) (p<0.05; Student’s ttest).
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Figure 2.6. Increased inulin provision abolishes effects of PCB 126 treatment on
fermentative SCFA production by isolated fecal bacteria

Figure 2.6. Increased inulin provision abolishes effects of PCB 126
treatment on fermentative SCFA production by isolated fecal bacterial.
Bacterial cell suspensions were maintained on inulin substrate (10g/L) and
subsequently exposed to PCB 126 (0.02 µM, 0.2 µM, 2 µM) or vehicle control
(DMSO) for 48h (n=3). HPLC was utilized to quantify fermentation acids in the
media after incubation. PCB 126 had no significant effect on fermentation acid
production from a higher inulin substrate concentration (10 g/L). There was a
trend towards lower total fermentation acid production (p=0.055) in bacterial
cultures exposed to higher levels of PCB 126. All data are presented as means
+ SEM. * Significantly different compared to vehicle control (DMSO) (p<0.05;
Student’s t-test)
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Chapter 3

Dioxin-like PCB 126 increases inflammation and disrupts gut
microbiota and metabolic homeostasis
Environmental Pollution: PMID: 30373033

Jessie B. Hoffman*, Michael C. Petriello*, Olga Vsevolozhskaya, Andrew J.
Morris, Bernhard Hennig [143]
* both contributed equally to manuscript
3.1

Synopsis
The gut microbiome is sensitive to diet and environmental exposures and

is involved in the regulation of host metabolism. Additionally, gut inflammation is
an independent risk factor for the development of metabolic diseases, specifically
atherosclerosis and diabetes. Exposures to dioxin-like pollutants occur primarily
via ingestion of contaminated foods and are linked to increased risk of
developing cardiometabolic diseases. We aimed to elucidate the detrimental
impacts of dioxin-like pollutant exposure on gut microbiota and host gut health
and metabolism in a mouse model of cardiometabolic disease. We utilized 16S
rRNA sequencing, metabolomics, and regression modeling to examine the
impact of PCB 126 on the microbiome and host metabolism and gut health. 16S
rRNA sequencing showed that gut microbiota populations shifted at the phylum
and genus levels in ways that mimic observations seen in chronic inflammatory
diseases. PCB 126 reduced cecum alpha diversity (0.60 fold change; p=0.001)
and significantly increased the Firmicutes to Bacteroidetes ratio (1.63 fold
change; p=0.044). Toxicant exposed mice exhibited quantifiable concentrations
of PCB 126 in the colon, upregulation of Cyp1a1 gene expression, and increased
markers of intestinal inflammation. Also, a significant correlation between
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circulating Glucagon-like peptide-1 (GLP-1) and Bifidobacterium was evident and
dependent on toxicant exposure. PCB 126 exposure disrupted the gut microbiota
and host metabolism and increased intestinal and systemic inflammation. These
data imply that the deleterious effects of dioxin-like pollutants may be initiated in
the gut, and the modulation of gut microbiota may be a sensitive marker of
pollutant exposures.

3.2

Introduction
Pollutant exposures are associated with numerous chronic inflammatory

cardiometabolic diseases including cardiovascular diseases (CVD), obesity, and
diabetes [168-170]. Dioxin-like pollutants are a class of highly toxic lipophilic
compounds known to accumulate in the adipose tissue of living animals and
thus biomagnify up the food chain [168]. Using preclinical animal models
including Ldlr and ApoE deficient mice as a tool to study cardiometabolic
disorders, multiple groups have shown that dioxin-like pollutants can impact
multiple pathologies through mechanisms that include induction of chronic
inflammation in various organ systems [38, 171, 172]. The most common route
of human exposure to these pollutants comes from consumption of contaminated
food sources and because of this, the intestinal environment is a target organ
that deserves further study.
The gut is home to trillions of bacteria which are sensitive to many factors
including diet and environmental exposures [173]. Additionally, the gut
microbiome plays an essential role in the maintenance of energy metabolism,
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immune function, neurological function, and overall host health and well-being
[173]. Commensal bacteria exist in a mutualistic relationship with the host, relying
on host energy and nutrient intake, and in turn, the gut microbiota protect against
pathogen invasion, influence immune function, maintain gut barrier integrity, and
produce metabolites that exert various effects on host physiology [173].
Therefore, alterations in gut microbial composition can have deleterious effects
on host health. Such alterations are termed “dysbiosis” and have been
associated with increased risk of cardiometabolic diseases [174, 175]. Dysbiosis
is commonly associated with a decrease in gut microbial diversity, an aspect that
has been consistently observed in mice fed atherogenic diets, and human
pathological conditions such as atherosclerosis and diabetes [108]. Also,
chronic gut and systemic inflammation accompanies the observed disruption of
gut flora homeostasis in these pathologies.
Chronic inflammation is an underlying aspect in many non-communicable
diseases and has been strongly linked to contributing to the development of
cardiovascular diseases (e.g., atherosclerosis) [176]. Atherosclerosis is
influenced by inflammation through a variety of mechanisms including cytokine
production and release, production of reactive oxygen species, and certain
immune responses [176]. Additionally, it is well documented that low-grade
chronic inflammation precedes and is predictive of the development of
cardiometabolic diseases in adults [177]. Emerging evidence now implicates a
critical role of gut microbiota in systemic and intestinal inflammation, which may
impact on other peripheral organ systems (e.g., vascular tissue) [174]. The

61

initiation of these inflammatory processes that exert effects on the cardiovascular
and metabolic systems, as well as the gut microbiota can come from behavioral
factors such as diet as well as less-modifiable aspects including genetics and
environmental pollutant exposure.
Although there is a large body of evidence linking dietary behaviors to
modulation of gut microbiota, only a few studies have examined the interplay
between persistent organic pollutants (POPs) and the gut microbiota. Zhang et
al, found that exposure to 2,3,7,8 tetrochlorodibenzofuran in mice resulted in
alterations in gut microbiota, bile acids, and short chain fatty acid (SCFA)
metabolism [178]. Additionally, exposure to benzo[a]pyrene induces intestinal
inflammation, ileal lesions, and shifts gut microbiota populations [19]. When
examining the effects of polychlorinated biphenyls (PCBs), Choi et al. observed
disruptions of intestinal barrier function through dysregulation of tight junction
proteins [18]. In a later study, Choi et. al found that exposure to a mixture of
PCBs (PCB 153, PCB 138, PCB 180) acutely altered the gut microbiota and that
exercise was able to blunt these effects [179]. Although pollutant exposures
have been shown to modulate gut microbiota in wild-type mice, it is not well
established if dioxin-like pollutants can modulate gut microbiota in mice
genetically predisposed to cardiometabolic disease. In humans, diabetes and
related pathologies regularly accompany or exacerbate atherosclerosis, thus,
utilizing Ldlr deficient mice is a useful tool to study multiple diseases related to
metabolic dysfunction [180]. Therefore, the specific objective of this study was to
elucidate effects of the model dioxin-like pollutant PCB 126 on gut health, gut
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microbiota, and metabolism in a well-established mouse model of
cardiometabolic disease.

3.3

Materials and Methods

3.3.1 Animals, diet, and study design
The diet and dosing schedule utilized for this study was shown previously
to be an effective model of PCB 126-accelerated atherosclerosis [181]. The
results described herein were collected from a subset of mice from our previous
study [181]. Briefly, seven week-old male Ldlr -/- mice were purchased from
Jackson Laboratories (Bar Harbor, ME, USA) and were randomly divided into 2
groups (n = 10 per group) with one group receiving 1 µmol/kg of PCB 126
(AccuStandard, CT, USA) and the other group receiving safflower oil vehicle
(Dyets, Bethlehem, PA, USA) via oral gavage at weeks 2 and 4. This dose
produces plasma PCB 126 levels that mimic human exposures of dioxin-like
pollutants (Petriello et al. 2017). All mice were fed a low-fat high cholesterol
Clinton/Cybulsky diet ad libitum (Research Diets, New Brunswick, NJ, USA;
Product # D01061401C). Mice were housed at 22oC with 50% humidity,
exposed to a 12-h light/ 12-h dark cycle, and given water ad libitum. Fecal
samples were collected at 72h, 4 weeks, and at sacrifice (12 weeks) after first
PCB 126 exposure. Prior to euthanasia, mice were fasted overnight,
anesthetized, and blood was collected using retro-orbital bleed. At the
conclusion of the study, intestinal samples, cecum, and cecum contents were
also collected and immediately snap frozen in liquid nitrogen and stored at -80oC
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until analysis. All experimental procedures were approved by the Institutional
Animal Care and Use Committee at the University of Kentucky.

3.3.2 DNA extraction and 16S rRNA amplicon library preparation and
sequencing
DNA extraction and 16S sequencing was conducted by the Environmental
Sample Preparation and Sequencing Facility (ESPSF) at Argonne National
Laboratory and analyzed by the program Quantitative Insights Into Microbial
Ecology (QIIME). DNA was extracted using PowerSoil 96-well DNA Isolation Kit
(MoBio, Carlsbad, CA, USA), according to the manufacturer’s protocol with the
addition of a 65oC heating step after the addition of solution C1. PCR amplicon
libraries targeting the 16S rRNA encoding gene present in metagenomic DNA
were produced using a barcoded primer set adapted for the Illumina HiSeq2000
and MiSeq, and DNA sequence data was generated using Illumina paired-end
sequencing [81]. The V4 region of the 16S rRNA gene (515F-806R) was PCR
amplified with region-specific primers that include sequencer adapter sequences
used in the Illumina flowcell. The conditions for PCR were as follows: 94°C for 3
minutes to denature the DNA, with 35 cycles at 94°C for 45 s, 50°C for 60 s, and
72°C for 90 s; with a final extension of 10 min at 72°C to ensure complete
amplification. Amplicons were quantified using PicoGreen (Invitrogen, Carlsbad,
CA) and a plate reader (Infinite 200 PRO, Tecan, Männedorf, Switzerland) and
then pooled into a single tube so that each amplicon is represented in equimolar
amounts. This pool was then cleaned up using AMPure XP Beads (Beckman
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Coulter, Brea, CA), and quantified using a fluorometer (Qubit, Invitrogen,
Carlsbad, CA). After quantification, the molarity of the pool was determined and
diluted to 2 nM, denatured, and diluted to a final concentration of 6.75 pM with a
10% PhiX spike for sequencing on the Illumina MiSeq. Amplicons were
sequenced on a 151bp x 12bp x 151bp MiSeq run using customized sequencing
primers and procedures. Operational taxonomic units (OTUs) were selected
using open reference OTU picking against the Greengenes database and picked
at 97% sequence identity. OTUs were then filtered based on the default
parameters provided by QIIME and sequences were rarified to a sampling depth
of 10000 reads per sample. Before statistical analyses, OTUs present in less
than 50% of samples were filtered from the OTU table.

3.3.3 RNA extraction and qPCR
For mRNA extraction, intestinal samples from jejunum and colon were
homogenized in TRIzol (Invitrogen, Carlsbad, CA) and isolated according to
manufacturer’s protocols. mRNA quality and concentrations were determined
using a NanoDrop 2000 spectrophotometer (Thermo Scientific, Waltham, MA).
Complementary DNA was generated using the AMV reverse transcription system
(Promega, Madison, MI) following manufacturer’s protocols. Expression of
inflammatory, metabolic, and gut health markers were determined via
quantitative qPCR utilizing Taqman fast reagents (Thermo Scientific, Waltham,
MA) in an CFX96 Real-Time PCR system (Bio-Rad, Hercules, CA). β-actin was
used as the housekeeping gene for jejunum and 18S was used as the
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housekeeping gene for colon. Differences in gene expression were calculated
using ΔΔCt relative quantification compared to control animals
3.3.4 Analyses of circulating cytokines and proteins related to metabolic function
To measure plasma metabolic hormones and cytokines the Milliplex Map
Mouse Metabolic Hormone Magnetic Bead Panel- Metabolism Multiplex Assay
and the Milliplex Map Mouse Cytokine/Chemokine Magnetic Bead Panel 25-plex
(Millipore Corp, Billerica, MA, USA) were used, respectively, following
manufacturer’s protocols. Panels were measured on the Luminex Xmap
MAGPIX system (Luminex Corp, Austin, TX, USA) following manufactures
instructions. For statistical analyses, values below the standard curve were
represented as zero.

3.3.5 Metabolomics analysis
At the conclusion of the study, livers were snap frozen and shipped to Metabolon
(Durham, NC) for targeted metabolomics analysis as detailed previously [182].
Briefly, Samples were prepared using the automated MicroLab STAR (Hamilton
Company, Reno, NV) and analyzed by Ultrahigh Performance Liquid
Chromatography-Tandem Mass Spectroscopy (UPLC-MS/MS). All methods
utilized a Waters ACQUITY ultra-performance liquid chromatography (UPLC) and
a Thermo Scientific Q-Exactive high resolution/accurate mass spectrometer
interfaced with a heated electrospray ionization (HESI-II) source and Orbitrap
mass analyzer. A series of proprietary standards of known concentration was
added to each sample extract. 4 separate analytical methodologies were utilized
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which were optimized depending on the characteristics of compounds of interest
(e.g., hydrophilic compounds vs. hydrophobic compounds). The MS analysis
alternated between MS and data-dependent MSn scans using dynamic exclusion.
For biochemical identification, three criteria were utilized: retention time, accurate
mass match to the library, and the MS/MS compared against authentic
standards. Peaks were quantified using area-under-the-curve. Short chain fatty
acids (SCFAs) were quantitated by the West Coast Metabolomics Center (Davis,
CA, USA). Briefly, SCFAs were extracted from feces samples using Tert-butyl
methyl ether, 2-ethylbutryic acid, and 4-methylvaleric acid and derivatized with Ntert-butyldimethylsilyl- N-methyltrifluoroacetamide (MTBSTFA). SCFAs were
quantitated using GCMS (Agilent GC7890B/5977MS) and absolute
concentrations were determined using calibration and internal standards.

3.3.6 Quantitation of atherosclerotic lesions and glucose sensitivity
To quantify atherosclerosis, aortic roots were frozen in OCT, sectioned at 10 µm
per section, and stained with Oil Red O as described before [181, 183]. Briefly,
serial sections were collected as close as possible to the emergence of the three
valves, and sections were placed on microscope slides (Probe-on Plus; Fisher
Scientific, Pittsburgh, PA) until the aortic valves disappeared. Frozen sections
were lipid stained with Oil Red O, and images were taken using a Nikon Eclipse
55iUpright microscope attached to a 12 MP color camera. For the results shown
in Suppl. Fig. 3, on average a mean of 6 serial sections per mouse were used for
quantification. To quantify glucose sensitivity a glucose tolerance test was
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performed at 5 and 12 weeks post initial PCB exposure. Mice were fasted for 6h
(7am-1pm), and fasting blood glucose levels were measured with a hand-held
glucometer (Accu-check Avivia, Roche,Basel, Switzerland) using 1-2μL of blood
collected through the tail vein. Glucose was given via IP injection (2mg/g body
weight, sterile saline) and blood glucose levels were measured at 15, 30, 60, 90,
and 120 minutes post injection.

3.3.7 PCB 126 Quantitation
PCB 126 from colons, livers, and plasma was extracted using a modified
dispersive solid phase extraction method as before [181]. Briefly, tissue/plasma,
internal standard (13C12-PCB 126; Cambridge Isotopes, Tewksbury, MA),
deionized water, and acetonitrile containing 1% acetic acid were added to each
tube and homogenized. The upper layer was transferred to an Agilent
Bond Elut QuEChERS fatty sample dispersive 2 ml SPE column. PCB 126 was
analyzed using an Agilent GC-triple quadrupole MS (GC-MS/MS) 7000C system
equipped with a multimode inlet and a HP-5MS UI column (30m, 0.25mm,
0.25μm) in multiple reaction monitoring (MRM) mode. Ion transitions monitored
were 325.9/255.9 for PCB 126 and 337.9/267.9 for 13C12-PCB 126 internal
standard. Relative quantitation was done by comparing peak area of the sample
to peak area of an internal standard sample of known concentration.
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3.3.8 Lipopolysaccharide Binding Protein Quantitation
Circulating levels of LBP were determined by ELISA per manufacturer’s
instructions (Cell Sciences, Newburyport, MA, USA). Briefly, plasma samples
were diluted 1:800 in dilution buffer and absorbance (450nm) was read using a
Cytation5 imaging plate reader (Biotek, Vermont, USA).

3.3.9 Statistical analyses
qPCR and MAGPIX results were analyzed using a Student’s t-test to
compute comparisons of means between treatment groups. Analyses were
conducted using GraphPad Prism (GraphPad Software, Inc., La Jolla, CA).
Metabolomics results were analyzed using a Welch’s two-sample t-test (n=6 per
group). These analyses were performed using ArrayStudio (Qiagen, Hilden,
Germany) on log transformed data.
For statistical analyses of changes in fecal bacterial genera over time,
linear mixed-effects model was utilized with unstructured correlation matrix
accounting for dependence among observations over time and within an animal.
Tukey’s pair-wise multiple comparison procedure followed to assess the
significance of change in bacterial genera at each time point. Gut hormones and
metabolic markers were correlated with bacterial species using one of the three
hypothesized linear models: the full model that accounted for a possible
interaction between PCB 126 exposure and a biomarker on the gut hormones
level; the reduced model that had an additive effect of PCB 126 exposure and a
metabolic biomarker only; and the simple model that did not account for the PCB
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126 exposure. The most appropriate model was determined based on the largest
value of the adjusted-R2, and its results were Bonferroni-adjusted to account for
multiple comparisons. Results were considered statistically significant with an
observed p-value <0.05.

3.4

Results

3.4.1 PCB exposure induces shifts in bacterial populations over time
It is hypothesized that the gut microbiota of Ldlr -/- mice will shift as
cardiometabolic disease progresses, but it is unknown if pollutant exposures will
exacerbate or modify these changes. Using 16S rRNA sequencing and the
QIIME analysis platform, we quantified the bacterial populations in fecal samples
collected 72 h, 4 weeks, and 12 weeks after first PCB or vehicle gavage
(depicted as phyla level changes in Figure 3.1 and genera level changes in
Figure 3.2). At the phyla level, PCB 126 decreased relative Bacteroidetes (0.75
fold change, p=0.011) and increased relative Verrucomicrobia (1.41 fold change,
p=0.008) and species in the feces at 4 weeks post gavage, but not at 12 weeks.
Using these relative abundances, we then analyzed the Firmicutes to
Bacteroidetes ratio over the four timepoints (Figure 3.1B). We found that in
general this ratio increased throughout the study for all mice (which was
expected as mice were fed the atherogenic diet), but interestingly, PCB treated
mice had a significantly higher ratio at the conclusion of the study in both feces
and cecum contents (feces: 3.29 fold change, p=0.0332; cecum: 1.63 fold
change, p=0.044).
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Next, using mixed-effects modeling, we increased the resolution of our QIIME
analyses to determine which genera differed between PCB and vehicle-treated
mice over time. In general, we determined four major trends with which generas
changed over time. The first pattern was one in which PCB-treated mice
displayed decreased bacterial genera abundance, while the abundance of
vehicle-treated mice was stable across the course of the study. For instance, by
the conclusion of the study, Lactobacillus genera in PCB-treated mice decreased
by 84% relative to the baseline values (Tukey-adjusted pTA = 0.0021) and was
80% lower than that of the vehicle-treated mice (pTA = 0.0339), among which the
abundance of Lactobacillus genera did not appreciably change from baseline
measurements (Figure 3.2A). The second pattern was one in which neither
vehicle nor PCB-treated mice displayed a statistically significant deviation from
each other or from the baseline genera values. For example, the abundance of
Oscillospira genera was not affected by PCB exposure, nor did it change or over
time (Figure 3.2B). The third pattern was one in which PCB-treated mice
displayed increased abundance over time, while the abundance among vehicletreat mice did not change. For example, by the conclusion of the study, the
abundance of Clostridiales genera was 420% higher among PCB-exposed mice
than among vehicle-treated mice (pTA = 0.0248; Figure 3.2C). Finally, the last
pattern was one in which both vehicle and PCB-treated mice displayed increased
abundance over time, but this difference was equivalent between the two groups.
For example, relative to the baseline levels, the abundance of Allobaculum
genera increased over tenfold by the conclusion of the study in both groups
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(week 14) (both pTA < 0.0001; Figure 3.2D). A summary of all temporal results
can be found in Supplemental Table 1.
3.4.2 PCB exposure alters cecal microbial diversity and bacterial genera
The cecum contains the greatest abundance of microbiota and is a primary site
of fermentation and bacterial metabolism. Using 16S rRNA sequencing and
QIIME analysis software, we also examined the bacterial populations in cecum
samples collected at the end of the study (week 14). Similarly to the fecal
results, PCB 126-treated mice exhibited significantly reduced relative
Bacteroidetes (0.38 fold change, p=0.002) and Firmicutes (0.54 fold change,
p=0.004) and greater relative Verrucomicrobia (1.71 fold change, p=0.021)
abundances compared to vehicle control (Figure 3.1A). Alpha diversity is a
common measurement of microbial diversity within a sample and takes into
account the richness (count of different microbes) and evenness (distribution of
different microbes) of a sample. PCB 126 decreased the alpha diversity
(Shannon diversity index) in cecal samples compared to vehicle control (0.60 fold
change, p=0.001) (Figure 3.3A). We also examined beta-diversity in these
samples and determined that PCB-exposed mice exhibited a significant
difference in microbial community structures compared to vehicle treated mice
(R=0.2924, p=0.010) (Figure 3.4). We next examined genera level changes in
the cecum contents and determined this source of bacteria to be more sensitive
to pollutant-induced changes compared with the fecal samples from the same
timepoint (i.e., conclusion of study). The abundance of S24.7 and Clostridiales as
well as the genera Bifidobacterium, Lactobacillus, Ruminococcus, and
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Oscillospira were all significantly decreased in PCB exposed mice by similar
magnitudes compared to vehicle control (0.39-0.90 fold change). Furthermore,
PCB 126 increased the abundance of Akkermansia (1.71 fold change, p=0.021)
in the cecal samples compared to vehicle control (Figure 3.3B).

3.4.3 PCB exposure increases systemic inflammation and alters
cardiometabolic disease parameters
Systemic inflammation may be a marker of altered gut health and has been
shown to be increased by PCB 126 [40, 181, 184]. Using MAGPIX multiplex
technology, we quantified the levels of circulating cytokines in plasma at the
conclusion of the study and found that PCB 126 significantly increased interferon
gamma-induced protein (IP-10; Figure 3.5A). Additionally, macrophage
inflammatory protein-1β (Mip-1β), regulated on activation, normal T cell
expressed and secreted (Rantes), and interleukin 12 (IL-12 p70) both increased
in PCB 126 exposed mice, however this increase did not quite attain the
statistical significance threshold (0.05 < p < 0.1). We also examined circulating
levels of LBP at the conclusion of the study and determined a slight trend toward
increased levels in PCB 126 treated mice (p=0.142; Figure 3.6) Since gut health
is also directly related to endogenous metabolism, we also quantified levels of
circulating mediators of glucose/insulin signaling and determined that PCB 126
significantly increased levels of insulin (2.74 fold change, p=0.019), c-peptide
(1.63 fold change, p=0.015), and glucose-dependent insulinotropic peptide (GIP)
(1.41 fold change, p=0.046) as well as significantly decreased levels of glucagon-
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like peptide 1 (GLP-1; Figure 3.5B) (0.31 fold change, p=0,048). At 5 weeks
post initial PCB gavage and again at the conclusion of the study, we completed a
glucose tolerance test and observed no significant differences in glucose
sensitivity during either of the challenges. However, fasting blood glucose of
PCB-exposed mice trended higher at both timepoints (p= 0.07, p= 0.16)
compared to vehicle treated controls (Figure 3.7). Finally, we quantified Oil Red
O-staining within aortic roots to examine the extent of atherosclerosis in these
mice. We previously showed acceleration of atherosclerosis due to PCB 126
exposure using this same model in studies of shorter duration (e.g., 8 or 10
weeks post first PCB gavage) [181]. We determined in this current study that
PCB-exposed mice displayed similar trends as seen before, but the differences
in lipid accumulation between the two groups was not as evident as in the shorter
studies (Mean control; 2.05x105 ± 2.53x104 µm2, Mean PCB; 2.60 x105 ±
3.42x104 µm2, p=0.2; Figure 3.8).

3.4.4 The intestine is a target of PCB 126 toxicity
There is currently limited evidence that PCB 126 can elicit an inflammatory
response in intestinal tissue [18, 185]. Thus, we utilized qPCR to examine gene
expression of markers related to inflammation, gut health, and metabolism in the
jejunum (small intestine) and the colon (large intestine). In general, PCB 126
elicited similar responses in both the jejunum and colon (Figure 3.9A and 3.9B).
PCB 126 significantly increased expression of Cyp1a1, a marker of aryl
hydrocarbon receptor (AhR) activation, in the jejunum and the colon (11.23 fold
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change, p<0.0001; 23.00 fold change, p<0.0001). Additionally, PCB 126
increased expression of the inflammatory markers hepcidin (Hamp) and tumor
necrosis factor alpha (Tnfα) in the colon and interleukin 6 (Il-6) and interleukin 18
(Il-18) in the jejunum. Expression of the tight junction proteins occludin (Ocel)
and claudin (Cldn3) were significantly increased only in the colon. Furthermore,
mucin 2 (Muc2) only trended towards increased expression by PCB 126 in the
colon (0.05 < p < 0.1). Toll like receptor 4 (Tlr4), a transmembrane receptor that
functions in pathogen recognition and activation of innate immunity, was
significantly decreased in the jejunum and colon of PCB 126 exposed mice.
Interestingly, peroxisome proliferator-activated receptor delta (Pparδ), an
important regulator of intestinal cell differentiation and potential inhibitor of
inflammatory bowel disease, was significantly decreased in the colon of PCB
treated mice (0.46 fold change, p=0.008). Gene expression of glucagon (Gcg),
the gene responsible for the production of glucagon like peptide 1 (GLP-1), was
significantly increased in both the jejunum and colon of PCB treated mice.
Finally, to better elucidate the presence of PCB in gut tissue, and possible
causative mediator of gut inflammation, we followed up these gene expression
observations by quantitating PCB 126 in colon tissue via GC-MS and determined
that the average concentration was 0.767 + 0.608 (Mean + S.E.M.) pmoles/mg
tissue. In comparison, hepatic levels averaged 6.388 + 0.688 (Mean + S.E.M.)
pmoles/mg and plasma levels were undetectable in most mice analyzed.
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3.4.5 PCB 126 alters hepatic metabolism in ways that mirror metabolic diseases
With the close proximity of the gut and liver, hepatic metabolism and gut health
are tightly intertwined, exerting continual influence on each other. It is known
that changes in hepatic metabolism occur as cardiometabolic disease
progresses, but it is unknown if dioxin-like pollutant exposure can modify global
metabolomic pathways in mice genetically predisposed to cardiometabolic
disease. Thus, using metabolomics-based approaches we next examined the
impact of PCB 126 on multiple metabolites related to glycolysis, lipogenesis, and
gut microbiota (Table 3.2). PCB 126 exposure significantly decreased glycolytic
intermediates including glucose 6-phosphate, 2-phosphoglycerate, and 3phosphoglycerate and increased glycerol, glycerol 3-phosphate, and 3hydroxybutyrate. Furthermore, we observed PCB induced alterations in
metabolites that can be influenced by interactions between gut microbiota and
host systems including reductions in N-acetylphenylalanine, hippurate, and 5hydroxyindoleacetate, and elevations in dimethylglycine, N-oleoyltaurine, and Omethyltyrosine. There were no differences in other gut microbe-influenced
metabolites in the liver including indolelactate, indole-3-carboxylic acid, and 3indoxyl sulfate. Finally, we completed fecal short chain fatty acid analysis at the
conclusion of the study and determined that PCB 126 significantly decreased
formic acid concentrations by nearly half (p=0.002). Acetic, butyric, isovaleric, or
propionic acids were not changed between groups (Table 3.3).
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3.4.6 PCB 126 induced bacterial alterations associated with metabolic markers
Finally, little is still known about how alterations in gut microbiota are related to
overall host health, therefore, using regression analysis we examined the
relationship between quantitative markers of inflammation and metabolism with
cecal bacterial genera counts. In general, of the correlations examined, there
were very few statistically significant associations between cecal genera counts
and circulating mediators of metabolism and inflammation. For example, no
significant association was observed between any of the cecal generas and Il-6,
c-peptide, GIP, or insulin. However, we did observe a statistically significant
association between absolute counts of Bifidobacterium and GLP-1 (Figure
3.9a). Specifically, there was a positive association between Bifidobacterium
counts and GLP-1 among PCB-treated mice (Bonferroni-adjusted p-value for the
number of generas considered pBA = 0.044), while among vehicle-treated mice
GLP-1 levels were decreasing with an increase in Bifidobacterium counts (pBA =
0.031). Furthermore, we also observed an inverse association between
Akkermansia and fasting blood glucose in both PCB 126 exposed mice and
vehicle treated mice (Figure 3.9b). Moreover, at the conclusion of the study,
overall fasting glucose levels were 23 points higher (pBA = 0.0342) among PCBtreated mice than among unexposed mice (Figure 3.9b).

3.5

Discussion
Currently, a major exposure source of dioxin-like pollutants such as PCB

126 is through consumption of contaminated foods [2]. Thus, the gastrointestinal
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system is susceptible to a relatively high concentration of pollutants but is a
comparably under studied target organ. Importantly, the gut can have drastic
impacts systemically because of its critical role in maintenance of overall health
[92]. We previously showed that PCB 126 could accelerate atherosclerosis and
increase systemic inflammation in mice genetically predisposed to
cardiometabolic disease, but any impacts of PCB 126 on gut microbiota in this
model were yet to be examined [181]. Therefore, in this study we employed the
same Ldlr -/- mouse model fed a high cholesterol diet to examine the effect of
PCB 126 on gut microbiota populations, gut health, and the interplay of these
effects with inflammation and metabolic complications. We observed that PCB
126 dramatically altered gut microbial populations, primarily in the cecum, and
consistently increased intestinal and systemic inflammation.
The gut microbiota are very sensitive to environmental factors including diet
and pollutant exposure. Dysbiosis, or the abnormal distribution of bacterial
populations, is associated with numerous health conditions from inflammatory
bowel diseases to obesity and cardiometabolic disease [92]. In these conditions,
an increase in the ratio of Firmicutes/Bacteroidetes has been consistently
observed and has been linked to increased susceptibility to inflammation,
infection, oxidative stress, and insulin resistance [186, 187]. In Figure 3.1B we
showed that this ratio was increased due to PCB 126 exposure by the end of the
study in both feces and cecum. Furthermore, individuals with type 2 diabetes,
have been demonstrated to have a unique microbial signature comprised of a
reduction in the number of Clostriadiales, including Roseburia spp, and

78

Faecalibacerium prausnitzii [188, 189]. In these patients with diabetes or insulin
resistance, it has been observed that these specific alterations in gut microbial
composition persist without alterations in carbohydrate metabolism [188, 189].
Research examining the relationship between cardiometabolic disease and gut
microbiota has been of great interest in the field lately. Studies have identified a
strong link between a gut microbial dependent metabolite, trimethylamine Noxide (TMAO), and the incidence of cardiometabolic disease [190-192]. In our
metabolomics work described herein we did observe an increase in
dimethylglycine, a possible TMAO precursor, but hepatic TMAO levels were not
significantly different between groups (plasma metabolomics was not completed).
Because the microbiota seems to have a strong ability to sense and respond to
systemic inflammation, examining known causes of inflammation, such as
pollutant exposure, on gut microbiota populations and functionality is greatly
needed.
There are only a few studies examining the effects of dioxin-like pollutant
exposure on gut microbiota and overall host health. Similarly, to what we
observed, Lefever et. al. found that TCDD exposure did not significantly affect
blood glucose homeostasis but did find distinct alterations in the gut microbiota
including an increase in the Firmicutes:Bacteroidetes ratio, which is commonly
seen in inflammatory disease conditions [193]. Additionally, another group
showed that exposure to TCDF induced similar changes to bacterial populations
as what we observe with PCB exposure [178]. For example, TCDF significantly
decreased the abundance of Firmicutes in the cecal contents similarly to what we
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observe in the cecal contents of our exposed animals. However, it is important to
note that TCDF exposure significantly reduced overall the Firmicutes:
Bacteroidetes ratio, opposite to what we observed with PCB exposure. Finally,
Choi et. al observed increases in Verrucomicrobia in the feces of PCB-exposed
mice, similarly to what we observe in the present study [179]. Although many of
these effects are similar to what we see in our current study, some differences
may be due to the unique model of cardiometabolic disease that the present
study utilizes.
Using 16S rRNA sequencing of fecal samples we examined the change in
bacterial populations over time (Figure 3.2). At the conclusion of the study, we
determined that PCB treated mice displayed a significant drop in S24.7 (30%)
and Lactobacillus (80%), as well as a significant increase in Clostridiales
(80.9%). The repeated collection of feces samples also revealed changes in gut
microbiota as cardiometabolic disease progressed in the Ldlr -/- mice. For
example, irrespective of treatment group, mice showed a significant ~70%
decrease in Lachnospiraceae (family) counts, a near ablation of Anaerostipes
counts, and a drastic increase (>1100 times) in Allobaculum from baseline to
study conclusion (Supplemental Table 1). Surprisingly, few studies in Ldlr or
ApoE -/- mice exist describing genera level changes throughout the progression
of cardiometabolic disease. There is some work looking at progressive changes
due to ageing and glucose intolerance/diabetes, but more work focused on
vascular diseases is needed [194, 195]. In addition to studying gut microbiota
changes over time using the collection of feces, we also examined gut microbiota
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differences due to PCB 126 at the conclusion of the study in cecum contents.
This medium was more sensitive to changes due to PCBs with significant
alterations in S24.7, Clostridiales, Akkermansia, Bifidobacterium, Lactobacillus,
Ruminococcus, and Oscillospira (Figure 3.3B).
Interestingly, all mice, regardless of treatment, exhibited high levels of
Verrucomicrobia (phylum level) and subsequently Akkermansia (genus level)
throughout the entirety of the study compared to what is typically observed in the
murine gut microbiota [149]. We hypothesize that the high cholesterol diet all
mice received caused an increase in Akkermansia. Although Akkermansia is
usually thought of as a healthful bacterial species, we are not the first to observe
increased abundance during high cholesterol feeding. Hamilton et. al reported
that an obesogenic diet may increase the level of this bacteria similarly to what
we observed [196]. Furthermore Carmody et al. observed a high proportion of
Verrucomicrobia and thus Akkermansia with high fat, high sucrose feeding [197].
Although the authors of both articles attributed this to the fat content, these diets
were also high in cholesterol which may be driving the increase in this bacterium
observed in both studies as well as ours. Further research needs to be done to
examine this effect.
We did observe that PCB 126 exposed mice exhibited higher cecum levels of
the phylum Verrucomicrobia and Akkermansia, a genus falling within this phylum,
at the end of the study, compared to vehicle treated mice. In support of this, a
smaller but still significant increase in Verrucomicrobia following PCB treatment
was observed by Choi et al [179]. The Akkermansia genus contains mucin
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degrading bacteria, specifically A. muciniphila, and there are reports that an
abnormally high abundance of Akkermansia may actually be detrimental due to
the excessive degradation of the mucus layer lining the intestine in such a way
that the mucin producing goblet cells cannot compensate [196, 198]. In support
of this, we observed trends toward an increase in mucin (Muc2) gene expression
in the colon of mice exposed to PCB 126. Although we did collect and
histologically stain Ileum tissues (H&E) in the current study, pathology analyses
did not reveal any conclusive differences between the two groups (necrosis was
observed in 50% of PCB treated mice and 33.3% of vehicle treated mice; data
not shown).
Overall, cecum bacterial populations were impacted to a greater degree by
PCB 126 exposure compared to feces. The cecum is characterized by a greater
abundance of bacterial species and is often more representative of actual gut
microbial populations than fecal samples [199]. We observed that PCB 126
exposed mice had reduced levels of the genera Oscillospira, Bifidobacterium,
Lactobacillus, and Ruminococcaceae. Oscillospira has recently been observed
to be positively associated with leanness and health while decreases in this
genera are observed in inflammatory diseases [200]. In our previous study,
utilizing the same mice, we showed that PCB 126 exposed mice had higher body
fat and lower lean mass percentages [181]. Bifidobacterium and Lactobacillus,
two of the most commonly recognized genera and prebiotics in the food system,
are both associated with improved gut health, glucose tolerance and reduced risk
of disease [120]. Specifically, lower levels of Bifidobacteria has been observed in
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the fecal microbiota of patients with irritable bowel syndrome, a condition
characterized by high levels of inflammation, while Lactobacillus spp.
supplementation has been demonstrated to aid in the prevention of intestinal
inflammation [201, 202]. Importantly, both Bifidobacterium spp. and
Lactobacillus spp. have been demonstrated to be increased by prebiotic
supplementation, which in turn was associated with improved glucose tolerance
and metabolic health [203, 204]. Thus, the reductions in these bacterial genera
in PCB treated mice may be associated with the observed alterations in
metabolic health.
To link the gut microbiota alterations to systemic inflammation and responses
to PCB 126 exposure, we conducted regression analysis examining the
relationship between markers of inflammation and metabolism with cecal
bacterial genera. Using this approach, we observed an inverse association
between Akkermansia and fasting blood glucose, regardless of treatment group.
This observation has been noted by other groups previously, demonstrating that
decreased levels of Akkermansia were associated with glucose intolerance and
supplementation of Akkermansia muciniphila to high fat fed mice improved
glucose tolerance [205]. Interestingly we observed a toxicant-dependent
association between Bifidobacterium and GLP-1, where increased levels of
Bifidobacterium were associated with increased levels of GLP-1, only in the PCB
126 treated group. This is important due to GLP-1’s involvement in managing
insulin levels. As such, it has been demonstrated that Bifidobacterium
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adolescentis supplementation improves insulin sensitivity in an animal model of
metabolic syndrome [206].
This current study is significant because we were able to examine PCB 126induced changes in gut health over time. Importantly, we observed that even 10
weeks following a final dose of PCB 126, gene expression of Cyp1a1 remained
highly elevated in the jejunum and colon. Cyp1a1 is a marker of AhR activation,
observed with exposure to PCB 126 and other dioxin-like pollutants. Our
observations of quantifiable levels of PCB 126 in the colons of exposed mice at
the end of the study highlight that PCBs have a long-lasting impact on the gut.
Other investigators have discussed the circulation of these pollutants through
enterohepatic circulation, which involves the cycling of drugs and other
compounds from circulation into the intestine where reuptake and transport to the
liver occurs [207]. Because we observed such an elevation in Cyp1a1 gene
expression, we hypothesize that these compounds are continually being cycled
through enterohepatic circulation, thus exerting a continual impact on the gut
microbiota and contributing to chronic increases in gut inflammation.
Intestinal inflammation poses a risk for systemic inflammatory and metabolic
conditions including diabetes and cardiovascular disease. For example, patients
with inflammatory bowel disease have increased endothelial dysfunction and
atherosclerotic lipid profiles [208]. This association with inflammatory diseases
and risk of cardiometabolic disease is well founded, for example in patients with
rheumatoid arthritis and psoriasis [209]. It is important to note that these
associations are independent of traditional cardiometabolic disease risk factors.
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Importantly, we observed increases in intestinal markers of inflammation
including Tnfα, Il-6, Il-18. In our previous study using the same model system,
we showed that PCB 126 increased circulating levels of multiple cytokines at 8
weeks post PCB gavage, but Tnfα and Il-6 were not changed. More work needs
to be completed to better understand how tissue specific inflammation (as we
see in the current study in the intestines) is related to an overall systemic
inflammatory response. It has been demonstrated that intestinal upregulation of
Il-18 results in production of chemoattractants and cytokines that can reach
circulation and initiate inflammatory responses systemically [210]. Interestingly, it
has been shown that the gut microbiota and antigen-presenting cells in the
intestine interact and stimulate the release of cytokines including TNF-α and IL-6
and that this results in the exacerbation of inflammatory bowel disease as well as
whole body inflammation [211]. Although we did see similar trends in our
previous work showing PCB 126 accelerated atherosclerosis at earlier time
points [181], this was no longer significantly different in mice sacrificed at 12
weeks post first PCB gavage. However, if we combined data points from our
previously published work and this current study to increase statistical power, the
acceleration of atherosclerosis due to PCB 126 becomes highly significant
(p=0.004; data not shown). It is not unexpected that as cardiometabolic disease
progresses in all of the Ldlr deficient mice, the impact of PCB 126 on
atherosclerosis is blunted at later time points. To investigate the impact of
dioxin-like pollutants in future longer-term studies, additional toxicant exposures
(i.e., additional gavages) may be useful. In fact, circulating levels in plasma of
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PCB 126 were undetectable in many of the mice examined at the end of this
current study. In our previous study [181] circulating levels of PCB 126 at 8
weeks post first PCB exposure were detected in all mice analyzed with an
average of 0.104 picomoles PCB 126/μL plasma.
We also observed some potentially adaptive responses to PCB 126. For
example, in the colon, we observed a reduction in Tlr4. Tlr4 is involved in the
inflammatory signaling response through its trigger of nuclear factor κ B. (NF-κB).
However, the observed reduction in expression of Tlr4 in PCB treated mice may
be in an attempt to attenuate the inflammatory responses already ongoing in the
intestine. Indeed, it has been demonstrated that in murine macrophages,
lipopolysaccharide stimulation actually resulted in the downregulation of Tlr4
[212]. Additionally, we observed a small increase in mRNA expression of tight
junction proteins in the intestine of PCB-exposed mice. We hypothesize that this
may also be a compensatory mechanism to repair following intestinal injury.
Future research should look at direct measures of intestinal permeability upon
pollutant exposure to better elucidate these effects. Additionally, our
observations of an increase in the bacterial genera Akkermansia was unexpected
and may also highlight potential compensatory mechanisms of pollutant
exposure. Although it is well established that Akkermansia is beneficial, others
have seen increases during proinflammatory events such as high fat feeding
[197, 198, 213]. These findings highlight the diverse roles that specific bacterial
populations may affect various disease states and the importance of follow up
studies using additional model systems.
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This is the first study to link PCB 126-induced disruption of the gut to changes
in systemic metabolism. We observed that PCB treated mice had increased
circulating levels of insulin, c-peptide, and glucose-dependent insulinotropic
peptide (GIP) and reduced levels of glucagon-like peptide 1 (GLP-1). While we
did not observe differences in glucose sensitivity during a glucose tolerance test
(Figure 3.7), the increased levels of insulin and c-peptide in PCB exposed mice
may indicate reduced insulin sensitivity (i.e., increased level of insulin required to
stimulate cellular glucose uptake). Furthermore, GLP-1 and GIP are both
insulinotropic incretins, but there is evidence that hyperinsulinemia and insulin
resistance can cause impairments in GLP-1 secretion from intestinal L cells
[214]. Because it is well understood that systemic inflammation can lead to
insulin resistance, we believe that the high level of inflammation observed in PCB
126 exposed mice is responsible for the dysregulation of insulin signaling and
subsequently further disruption of GLP-1 secretion from the intestine.
This disruption in metabolism was also observed in our hepatic metabolomic
analyses where we found that mice exposed to PCB 126 displayed disruptions of
glycolytic metabolism, evidenced by decreased levels of glucose 6-phosphate, 2phosphoglycerate, 3-phosphoglycerate, and phosphoenolpyruvate. Furthermore,
PCB 126 treated mice exhibited increases in glycerol, glycerol-3 phosphate, and
the ketone body 3-hydroxybutryate, indicating a shift towards a dominance of
fatty acid metabolism for energy resulting in ketone body formation. This shift
away from carbohydrate metabolism to fatty acid metabolism could be due to the
high circulating levels of insulin indicating a requirement for more insulin to
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stimulate glucose uptake, thus causing fatty acid utilization and ketone body
formation to be upregulated to meet energy demands more efficiently. Finally,
we also show for the first time that exposure to a dioxin-like PCB can decrease
fecal concentrations of a SCFA (formic acid). Interestingly, other SCFAs were
not altered in this study which may implicate the disruption of specific microbe
species by PCB 126. In future studies, higher resolution sequencing or the use
of species-specific qPCR primers, may be useful to better tease out the impacts
of lipophilic persistent organic pollutants on microbiota health.
Although this current study adds to a growing body of knowledge detailing the
impacts of persistent organic pollutants on gut microbiota and host health, there
are multiple limitations that may be more thoroughly addressed in follow-up
studies. First off, only an IP glucose tolerance test (GTT) was completed. As
more insulin may be released during an oral bolus of glucose, and with the
observed changes to incretins due to PCB 126, it is plausible that our glucose
tolerance observations may differ slightly depending on the administration
method. Secondly, since all mice received a high cholesterol diet to promote
cardiometabolic disease it is not possible to tease out how the interaction
between cholesterol and toxicant exposure is modulating gut microbe and host
health. A future, larger study, with a 2x2 factorial design (2-way ANOVA) would
be useful to tease out the effects of diet, toxicant exposure, and their interaction
on the observed changes. Finally, this study focused solely on male mice which
is an important consideration since the gut microbiota may differ between sexes
[215].
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Our current study demonstrates that exposure to PCB 126 in a
compromised model of cardiometabolic disease disrupts gut microbial
populations, contributes to intestinal inflammation, systemic inflammation, and
metabolic disruption. We hypothesize that the effects on systemic inflammation,
intestinal inflammation, and gut dysbiosis with PCB 126 exposure may occur
simultaneously and exert a feed-forward effect on each other. More studies are
needed to determine if toxicant-initiated changes in gut microbiota are a
causative mechanism linking exposures to dioxin-like pollutants to increased risk
of pro-inflammatory diseases in humans.
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Table 3.1. Gut microbiota population changes over time

Statistically significant differences determined by mixed-effects modeling of
absolute counts. † denotes statistical significance compared to baseline. ‡
denotes statistical significance between groups at specific timepoint. *median
instead of mean values are reported due to the skew in the distribution of the
absolute count values.

90

Table 3.2. Hepatic metabolomics analysis

Statisticaly significant differences determined by Welch’s two-sample t-tests. n=6 per group.
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Table 3.3. Fecal SCFA analysis

Bold text denotes statistically significant differences between groups as determined by student’s t-test. n=10 per group.
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Figure 3.1. Exposure to PCB 126 drives phyla level alterations in bacterial
populations over time
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Figure 3.1. Exposure to PCB 126 drives phyla level alterations in bacterial
populations over time. Male Ldlr-/- mice were fed an atherogenic diet for 14
weeks and exposed to PCB 126 (1µmol/kg) at weeks 2 and 4. Fecal samples
were collected at the start of the study, 72 hours, 4 weeks, and at sacrifice (12
weeks) post first PCB 126 exposure. Cecum contents were also collected at the
conclusion of the study. 16S rRNA sequencing was conducted and data was
analyzed using QIIME. A. Changes in the taxonomic composition of the gut
microbiota over time at the phylum level. Significant differences were observed in
the cecum contents at sacrifice. Cecum contents displayed a significant increase
in Verrucomicrobia and decreases in Firmicutes and Bacteroidetes. Data are
presented as relative abundances. B. Firmicutes / Bacteroidetes ratio changes
over time. PCB 126 increased the ratio of Firmicutes / Bacteroidetes in both the
feces and cecum contents at sacrifice. Data are presented as mean + S.E.M
(n=10 per group; Student’s t-test). Statistical significance is denoted by *
(p<0.05). # represents (p<0.1).
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Figure 3.2. PCB 126 modulates gut microbiota populations at the genra level
over time

Figure 3.2. PCB 126 modulates gut microbiota populations at the genra
level over time. Male Ldlr-/- mice were fed an atherogenic diet for 14 weeks and
exposed to PCB 126 (1µmol/kg) at weeks 2 and 4. Fecal samples were collected
at the start of the study, 72 hours, 4 weeks, and at sacrifice (12 weeks) post first
PCB 126 exposure. A representative example of each of the 4 observed trends is
depicted. For all generas, please see Table 3-1. A linear mixed-effects model
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was utilized with Tukey’s pair-wise multiple comparison procedure to assess the
significance of change in bacterial genera at each time point. Statistical
significance is denoted by * (p<0.05). (n=10 per group; Student’s t-test).
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Figure 3.3. Exposure to PCB 126 alters cecal bacterial genera and alpha
diversity

Figure 3.3. Exposure to PCB 126 alters cecal bacterial genera and alpha
diversity. Male Ldlr-/- mice were fed an atherogenic diet for 14 weeks and
exposed to PCB 126 (1µmol/kg) at weeks 2 and 4. Cecum contents were
collected at the conclusion of the study. (A) Alpha diversity of cecum contents
quantified using the Shannon Diversity Index. PCB 126 exposure decreased
alpha diversity in cecum contents. (B) Order and genera level changes in cecal
gut microbiota. PCB 126 decreased abundance of S24.7, Clostridiales,
Bifidobacterium, Lactobacillus, Ruminococcus, and Oscillospira and increased
Akkermansia abundance. Data are presented as mean + S.E.M (n=10 per
group; Student’s t-test). Statistical significance is denoted by * (p<0.05).

97

Figure 3.4. Principal coordinates analysis of unweighted UniFrac distances of
microbial communities in cecum contents

Figure 3.4. Principal coordinates analysis of unweighted UniFrac distances
the microbial communities in cecum contents. PCB 126- exposed mice
exhibited a significant difference in cecum microbial community structures
compared to vehicle treated mice (R=0.2924, p=0.01). Analysis of similarity
(ANOSIM) was used to identify microbial community differences.
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Figure 3.5. Analysis of circulating cytokines and biomarkers of energy
metabolism revealed that PCB 126 increases inflammation and alters insulin and
related markers

Figure 3.5. Analysis of circulating cytokines and biomarkers of energy
metabolism revealed that PCB 126 increases inflammation and alters
insulin and related markers. Male Ldlr-/- mice were fed an atherogenic diet for
14 weeks and exposed to PCB 126 (1µmol/kg) at weeks 2 and 4. Fecal samples
were collected at the start of the study, 72 hours, 4 weeks, and at sacrifice (12
weeks) post first PCB 126 exposure. (A) Quantification of circulating cytokines
(MAGPIX technology). PCB 126 increased Interferon gamma-induced protein
(IP-10) plasma levels. (B) Quantification of circulating markers of energy
metabolism (MAGPIX technology). PCB 126 increased plasma levels of insulin,
c-peptide, and glucose-dependent insulinotropic peptide (GIP). PCB 126 reduced
plasma levels of glucagon-like peptide 1 (GLP-1) Data are presented as mean +
S.E.M (n=9-10 per group; Student’s t-test). Statistical significance is denoted by *
(p<0.05).
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Figure 3.6. Plasma concentrations of lipopolysaccharide binding protein (LBP)
as determined by ELISA

Figure 3.6. Plasma concentrations of lipopolysaccharide binding protein
(LBP) as determined by ELISA. PCB exposed mice exhibited a trend towards
increased circulating levels of LBP at the conclusion of the study (p=0.142; n=8).
For group comparison, an unpaired t-test was used and significance was set at
p<0.05.
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Figure 3.7. No differences in glucose tolerance was observed between vehicle
and PCB 126-exposed mice at 5 or 12 weeks post exposure

Figure 3.7. No differences in glucose tolerance was observed between
vehicle and PCB 126-exposed mice at 5 or 12 weeks post exposure. Mice
were fasted for 6h (7am-1pm)., and fasting blood glucose levels were measured
with a hand-held glucometer (Accu-check Avivia, Roche, Basel, Switzerland)
using 1-2uL of blood collected through the tail vein. Glucose was given via IP
injection (2mg/g body weight, sterile saline) and blood glucose levels were
measured at 15, 30, 60, 90, and 120 minutes post injection. For group
comparison, an unpaired t-test was used for each timepoint and significance was
set at p<0.05
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Figure 3.8. PCB 126 exerts a modest increase in atherosclerosis development

Figure 3.8. PCB 126 exerts a modest increase in atherosclerosis
development. Male Ldlr -/- mice were fed a low fat, 0.15% cholesterol diet for 14
weeks and administered 1 μmol/kg PCB 126 at weeks 2 and 4. Aortic roots were
frozen and serially sectioned from the emergence of the 3 valves. On average,
the mean of 6 sections per mouse was utilized for quantitation. A. Shown are Oil
Red O stained aortic root sections of mice exposed to vehicle control or PCB 126
with associated lesion area quantification (n=9 control, n=8 PCB; p=0.21;
Student’s t-test).
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Figure 3.9. PCB 126 exposure increases intestinal inflammation and alters
markers of gut health

Figure 3.9. PCB 126 exposure increases intestinal inflammation and alters
markers of gut health. Male Ldlr-/- mice were fed an atherogenic diet for 14
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weeks and exposed to PCB 126 (1μmol/kg) at weeks 2 and 4. Intestinal samples
were collected at the conclusion of the study. mRNA units were determined using
the relative quantification method (ΔΔCT), normalized to control values. β-actin
was used as the housekeeping gene for all jejunum and 18S was used for all
colon gene expression quantifications. (A) Gene expression in the jejunum. PCB
126 increased expression of cytochrome p450 A1 (Cyp1a1), and markers of
inflammation such as interleukin 18 (Il-18), (B) Gene expression in the colon.
PCB 126 increased gene expression of Cyp1a1 and markers of inflammation
such as hepcidin (Hamp), tumor necrosis factor (Tnfα), Interleukin 6 (Il-6). PCB
126 increased tight junction protein gene expression including occludin (Ocel)
and claudin (Cldn3). Data are shown as mean + S.E.M. (n=10 per group;
Student’s t-test). Statistical significance is denoted by * (p<0.05).
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Figure 3.10. Exposure to PCB 126 drives phyla level alterations in bacterial
populations over time

Figure 3.10. Exposure to PCB 126 drives phyla level alterations in bacterial
populations over time. Male Ldlr-/- mice were fed an atherogenic diet for 14
weeks and exposed to PCB 126 (1μmol/kg) at weeks 2 and 4. Liver samples
were collected at the conclusion of the study. Correlations between gut microbes
and plasma markers were determined by linear regression modeling. GLP-1
levels were toxicant dependently associated with Bifidobacterium abundance
(unadjusted p=0.0126). Fasting blood glucose levels were inversely associated
with Akkermansia abundance, independent of toxicant exposure (unadjusted
p=0.0191). Intersection of lines denote significant interaction.
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Chapter 4
4.1

Characterization of the protective effects of prebiotic
consumption against PCB 126 toxicity

Synopsis

In chapter three it was demonstrated that exposure to PCB 126 increased
inflammation and disrupted gut microbiota and metabolic homeostasis. It is well
accepted that lifestyle modification (i.e. dietary changes and exercise) can
contribute to benefits in host health as well as protection from pollutant toxicity.
Due to our previously observed involvement and disruption of the gastrointestinal
tract and gut microbiota during PCB exposure, employing nutritional interventions
that have strong effects on these could be beneficial in attenuating PCB-health
detriments. Inulin is a well-studied prebiotic dietary fiber that has been
demonstrated to attenuate gut dysbiosis, improve glucose and lipid metabolism,
and reduce cardiometabolic disease risk, making it a suitable nutritional
intervention to combat the PCB-effects discussed in chapter three. Therefore,
our objective in the present study was to elucidate the role of prebiotic nutritional
intervention (i.e. inulin) on attenuating PCB-induced disruption of cardiometabolic
health and gut microbiota populations. Male Ldlr-/- mice were fed an atherogenic
diet containing 8% cellulose or 8% inulin for 12 weeks and exposed to PCB 126
(1µmol/kg) or vehicle at weeks 2 and 4. PCB exposure induced wasting and
impaired glucose tolerance, which was attenuated by inulin consumption.
Hepatic lipid accumulation, specifically microvesicularly, was observed with PCB
exposure and lessened with inulin consumption. To examine potential underlying
mechanisms contributing to these observed phenotypes, examination of
microbial populations, metabolic regulatory parameters, and inflammatory
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markers was conducted. 16S rRNA sequencing of gut microbial populations
revealed an overall diet effect of lowering the Firmicutes: Bacteroidetes ratio, a
common observation observed in metabolically healthy individuals [80].
Additionally, diet and exposure induced specific alterations in microbial
populations at the genera level and are described within Table 4.2. It was also
observed that PCB-induced disruption in glycolytic and gluconeogenic enzyme
expression, which was improved by inulin feeding and may play a role in the
improvements in glucose tolerance we observed in inulin fed mice. Finally, PCB
exposure increased the hepatic levels of ceramides, a biomarker of
cardiometabolic disease, and that inulin consumption reduced these levels,
suggesting a protective role of inulin against cardiometabolic disease. Our
current data of this ongoing study demonstrate that dietary intervention (i.e.
inulin) is an effective means at attenuating PCB-induced metabolic disruption,
inflammation, and gut microbial modulations, potentially reducing the risk of
cardiometabolic disease.
4.2

Introduction
The burden of environmental pollutant exposure continues to increase

worldwide, despite reductive efforts [2-4]. Exposure to dioxin-like pollutants
poses numerous health risks for an individual including increased risk of
cardiometabolic diseases such as atherosclerosis and diabetes [2, 3]. Due to the
lipophilic nature of dioxin-like pollutants, humans are primarily exposed through
consumption of contaminated of fatty foods such as fatty fish, beef, and dairy
products [2, 38]. Importantly, this route of exposure allows for the
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gastrointestinal tract to receive the highest levels of dioxin-like pollutants and
therefore makes it a critical aspect to study. The gut and gut microbiota play an
important role in overall host health and disruptions in these systems have been
implicated in the development of several diseases including cardiometabolic
diseases [80]. Our lab has previously demonstrated that exposure to the dioxinlike pollutant PCB 126 increases intestinal inflammation, disrupts gut microbiota,
and alters host metabolism, and can accelerate development of cardiometabolic
disease [143, 181]. Furthermore, the data discussed in chapter two
demonstrated that PCBs can exert toxic effects on specific bacterial populations
through membrane disruption, leading to disruption in microbial metabolite
production that may negatively affect the host. Because of these findings
demonstrating the toxicity of PCBs on the gut microbiota and gut health,
utilization of dietary interventions by which to attenuate or reverse these negative
effects may be a sensible means of reducing disease risks associated with PCB
exposure.
Prebiotics are defined as “a selectively fermented ingredient that allows
specific changes both in the consumption and/or activity in the gastrointestinal
microbiota that confers benefits upon host well-being and health” [124]. The
most widely understood and accepted prebiotics include certain types of dietary
fiber [125]. Dietary recommendations for dietary fiber intakes are at least 28g
and 35g for females and males, respectively. However, it has been documented
that less than 3% of Americans are meeting these recommendations, highlighting
an important avenue for improvement and intervention [125]. Not all dietary
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fibers are prebiotic and modulate the microbiota. Fibers that have been
documented to have functional prebiotic properties include
fructooligosaccharides, galactooligosaccharides, some disaccharides, some
nonstarch polysaccharides, and inulin [126]. The prebiotic inulin is an inulin type
fructan that contains linear chains of fructosyl groups linked by (2-1) glycosydic
bonds, terminated with an -D(1-2)-glucopyranoside ring group on the reducing
end [128]. Inulin is found in vegetables like garlic, onions, and asparagus, but
one of the most common forms of inulin commercially available is derived from
chicory root [128] . Inulin is a potent prebiotic that has been demonstrated to
have stimulatory effects on certain bacterial populations that have been
associated with good health, including Bifidobacterium spp, and Lactobacillus
spp [134]. Furthermore, inulin administration was shown to reduce deleterious
bacteria, such as the sulfate-reducing genus Bilophila [134, 135]. Aside from
modulation of the gut microbiota, consumption of chicory-derived inulin has been
demonstrated to reduce adiposity, improve glucose sensitivity [132, 133].
Importantly, inulin consumption can reduce hepatic lipogenesis and plasma
triglycerides as well as reduce atherosclerotic lesion formation, and thus may be
protective against PCB-induced hepatic steatosis and acceleration of
atherosclerosis [216, 217]. Thus, the objective of this study was to elucidate the
role of prebiotic nutritional intervention (i.e. inulin) on attenuating PCB-induced
disruption of cardiometabolic health and gut microbiota populations.
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4.3

Materials and Methods

4.3.1 Animals, diets, and study design
Seven-week-old male Ldlr -/- mice were purchased from Jackson
Laboratories and maintained on a 12-h light/ 12 h dark cycle at a temperature of
22oC with 50% humidity. All mice received food and water ad libitum and
measures of food intake and body weight were recorded weekly. The base diet
and dosing schedule for this study have been previously shown to be an
appropriate model of pollutant-accelerated cardiometabolic disease. Following
one week of acclimation, mice were randomly divided into 4 groups (n=10). Mice
were fed either a control high cholesterol diet containing 8% cellulose as the fiber
source (2 groups; n=10 each) or a prebiotic containing high cholesterol diet with
8% of inulin as the fiber source (2 groups; n=10 each). The level of fiber in this
study was chosen to represent a “high” fiber intake based on human dietary
recommendations. The recommended intake of fiber is 14g per 1000 calories
[218]. The traditional level of fiber in purified rodent diets is 5%, equating to 12g
per 1000 calories. The 8% level of fiber equates to 21g per 1000 calories, which
can be classified as a “high” fiber diet. Detailed diet compositions can be found
in Table 4.1. At weeks 2 and 4, mice received either 1 µmol/kg of PCB 126
(AccuStandard, CT, USA) or safflower oil vehicle (Dyets, Bethlehem, PA, USA)
via oral gavage. At the end of the study mice were fasted for 16 h, anesthetized
and blood was collected via retro-orbital bleed. Liver, intestinal samples, and
cecum samples were collected, snap frozen in liquid nitrogen, and stored at -80
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C until analysis. All experimental procedures were approved by the Institutional

Animal Care at the University of Kentucky.

4.3.2 Glucose tolerance testing and body composition analysis
Intraperitoneal GTTs were conducted on weeks 5 and 8. Mice were fasted for
6 h and given an IP injection of glucose (i.e. 20% solution at 2 mg/g BW, sterile
saline). Blood from the tail vein was collected at baseline, 15, 30, 60, 90, and
120 minutes post injection and blood glucose levels were quantified using a
hand-held glucometer (Accu-check Avivia, Roche, Basel, Switzerland). Lean
body mass and fat mass were analyzed at week 10 using EchoMRI (EchoMRI
LLC, Houston, TX, USA).

4.3.3 DNA Extraction and 16S rRNA Sequencing
DNA extraction and 16S rRNA sequencing were conducted by the
Environmental Sample Preparation and Sequencing Facility (ESPSF) at Argonne
National Laboratory as previously discussed. Analysis was conducted using the
program Quantitative Insights into Microbial Ecology (QIIME version 2.0) utilizing
parameters discussed in Petriello et. al. 2018 [143].

4.3.4 Hepatic histology
Sections of liver were fixed in 10% neutral buffered formalin and subsequently
embedded in paraffin for histological examinations. Hepatic tissues sections
were stained with hematoxylin-eosin (H&E) and examined by a pathologist via
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light microscopy and visually scored based on macrovesicular fat percentages.
Microvesicular fat accumulation was noted as “present” or “not present”.
Photomicrographic images were captured at 20x magnification using a highresolution digital scanner.

4.3.5 RNA Extraction and qPCR
Jejunum, colon, and liver samples were homogenized in TRIzol (Invitrogen,
Carlsbad, CA) and mRNA was extracted according to manufacturer’s
instructions. Quality and concentrations were quantitated using a NanoDrop
2000 spectrophotometer (Thermo Scientific, Waltham, MA). Complimentary
DNA was generated utilizing qScript cDNA SuperMix (Quantabio, Beverly, MA)
according to manufacturer’s protocols. Gene expression was determined via
qPCR utilizing Taqman fast reagents (Thermo Scientific, Waltham, MA) in a
CFX90 Real-Time PCR system (Bio-Rad, Hercules, CA). B-actin was used as
the housekeeping gene for intestinal samples and 18S was used as the
housekeeping gene for liver samples. The ΔΔCt relative quantification method
was used to calculate fold differences in gene expression.

4.3.6 Analyses of circulating proteins related to metabolic function
Plasma metabolic hormones were quantified using the Milliplex Map Mouse
Metabolic Hormone Magnetic Bead Panel- Metabolism Multiplex Assay (Millipore
Corp, Billerica, MA, USA) following manufacturer’s protocols. Assays were
measured on the Luminex Xmap MAGPIX system (Luminex Corp, Austin, TX,

112

USA) following manufactures instructions. For statistical analyses, values below
the standard curve were represented as zero.
4.3.7 Quantification of hepatic metabolites related to cardiometabolic disease
and metabolic function
To quantify levels of specific lipids, plasma was spiked with deuterium labeled
internal standard mixture and extracted using methyl tert-butyl ether. The
samples were analyzed using an Ultimate 3000 ultra high performance liquid
chromatography system coupled to a Thermo Q-Exactive Orbitrap mass
spectrometer equipped with a heated electrospray ion source (Thermo Scientific,
CA, USA). Lipid extracts were separated on a Waters ACQUITY BEH C8 column
(2.1 × 100 mm, 1.7 μm) with the temperature maintained at 40 °C. The flow rate
was 250 μL/min, and the mobile phases were consisted of 60:40
water/acetonitrile (A), and 90:10 isopropanol/acetonitrile (B), both containing 10
mM ammonium formate and 0.1% formic acid. The samples were eluted with a
linear gradient from 32 % B to 97 % B over 25 min, maintained at 97 % B for 4
min and re-equilibration with 32 % B for 6 mim.
4.3.8 Statistical analyses
Data were analyzed using GraphPad PRISM and are presented as mean +
SEM. Comparisons between groups were made by two-way ANOVA with posthoc comparisons of the means. Statistical significance was set at a determined p
value of p<0.05.
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4.4

Results

4.4.1 Inulin consumption and PCB exposure exert differential effects on body
composition
When examining body composition, it was observed that inulin consumption
resulted in an overall lower weight gain irrespective of exposure (Figure 4.1a).
Furthermore, cellulose fed mice exposed to PCBs had significantly greater
weight gain than exposed inulin fed mice. EchoMRI measurements of body
composition revealed that PCB exposure resulted in reductions in percent body
fat in cellulose fed mice, but not in inulin fed mice (Figure 4.1b). Importantly,
there were no differences in food intake between all of the groups (Figure 4.1c).

4.4.2 Inulin protects against PCB 126 disruption of glucose tolerance.
To assess the effects of pollutant exposure and inulin consumption on
glucose tolerance, an intraperitoneal glucose tolerance test (IGTT) was
conducted at weeks 5 and weeks 8. At week 5, PCB-exposure increased fasting
blood glucose levels in cellulose fed mice (Figure 4.2a). Such an increase was
not observed in inulin-fed mice. Furthermore, cellulose fed mice exposed to
PCBs displayed a greater area under the curve (AUC) compared in exposed
inulin fed mice. At week 8, no significant differences in fasting blood glucose
were observed, but the effects of PCB exposure and inulin feeding on AUC
observed at week 5 remained significant (Figure 4.2b). Importantly, no
differences in circulating insulin levels at the end of the study were observed
(data not shown).
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4.4.3 Inulin reduces PCB-induced hepatic steatosis
When examining liver composition, we observed that PCB exposure
significantly increased liver weight in cellulose fed mice, which was attenuated
with inulin consumption (Figure 4.3a). Overall, inulin-fed mice exhibited lower
liver weights compared to cellulose fed mice. A significant overall effect of PCB
exposure on increasing liver weights was apparent. Interestingly, PCB exposure
significantly reduced hepatic macrovesicular fat accumulation in cellulose fed
mice, however increases in microvesicular fat accumulation was evident in this
same group (Figure 4.3b). Overall, inulin fed mice exhibited lower
macrovesicular fat accumulation and an observation of lower microvesicular fat
accumulation in exposed inulin fed mice compared to exposed cellulose fed mice
was noted (Figure 4.3b).

4.4.4 Inulin and PCB 126 exert differential effects on gut microbial populations
Upon examination of gut microbial populations via 16S rRNA sequencing, we
observed several effects and interactions between pollutant exposure and inulin
consumption. At the phylum level, mice fed inulin had lower levels of
Verrucomicrobia than cellulose fed mice, irrespective of exposure (Figure 4.4a).
Furthermore, a significant increase in Actinobacteria in in all mice fed inulin
compared mice fed cellulose was observed and a significant increase in
Bacteroidetes was apparent in vehicle treated inulin fed mice compared to
vehicle treated cellulose fed mice (Figure 4.4a). There were no significant effects
of pollutant exposure on the Firmicutes to Bacteroidetes ratio, however a
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significant diet effect was observed in which inulin fed mice had a lower ratio than
cellulose fed mice (Figure 4.4b). Alpha diversity, as calculated using the
Shannon Diversity Index, revealed a significant exposure effect with PCB
exposed mice having a reduced diversity compared to non-exposed mice
(Figure 4.4c).
At the genera level, a significant increase in Coprococcus in cellulose fed
mice exposed to PCB 126 was found, which was attenuated by inulin feeding
(Figure 4.5). PCB exposed mice fed cellulose also exhibited a trend towards
reductions in Allobaculum which was significantly increased by inulin feeding
(Figure 4.5). Furthermore, inulin exposure significantly increased the abundance
of Bifidobacterium and Lactobacillus and reduced the abundance of
Ruminococcus. Inulin fed mice also exhibited lower levels of Akkermansia,
irrespective of pollutant exposure (Figure 4.5).

4.4.5 Inulin attenuates PCB-induced hepatic inflammation and alters markers of
xenobiotic metabolism
When examining hepatic gene expression of markers of inflammation, it was
observed that PCB exposure increased expression of tumor necrosis factor alpha
(Tnfα) and lipopolysaccharide binding protein (Lbp), which was attenuated by
inulin consumption (Figure 4.6a). Furthermore, exposed inulin fed mice also
exhibited reduced levels of toll like receptor 4 compared to exposed cellulose fed
mice. Furthermore, expression of hepcidin (Hamp) was lower in inulin fed mice,
irrespective of exposure (Figure 4.6a). Quantification of markers of pollutant
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exposure and detoxification revealed that PCB exposure induced expression of
cytochrome p450 (Cyp1a1) in both diets, however mice fed inulin exhibited
significantly lower levels compared to cellulose fed mice (Figure 4.6b).
Furthermore, exposed inulin fed mice exhibited lower levels of multidrug
resistance protein (Mrp2) compared to exposed cellulose-fed mice (Figure 4.6b).

4.4.6 Inulin reduces metabolites associated with cardiometabolic disease
To examine the effect of both PCB exposure and inulin feeding on
cardiometabolic disease risk, hepatic metabolites associated with
cardiometabolic disease were quantified. Using lipidomic analyses, it was seen
that in cellulose fed mice, PCB exposure increased hepatic levels of ceramide
species including 18:1/20:0 and 18:1/24:1 as well as total ceramides (Figure
4.7a). In exposed mice fed inulin, a significant reduction in ceramide species
18:1/20:0 was observed, with a trend towards reduction in species 18:1/24:1 as
well as total ceramides. Importantly, quantification of hepatic expression of
microsomal triglyceride transfer protein (Mttp), responsible for ceramide
transport, was decreased in PCB exposed mice fed cellulose and was rescued
with inulin feeding (Figure 4.7b) .

4.4.7 Inulin and PCBs differentially alter hepatic markers of glucose metabolism
and circulating metabolic hormones.
To elucidate the effects of PCB exposure and inulin consumption on glucose
metabolism, hepatic expression of key glycolytic and/or gluconeogenic enzymes
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was examined (Figure 4.8). PCB exposure significantly reduced expression of
pyruvate kinase (Pklr) in cellulose fed mice, while the reduction in exposed inulin
fed mice was not significant. Additionally, an overall reductive effect of PCB
exposure on glucokinase (Gck) and phosphoenolpyruvate carboxykinase (Pck1)
expression was observed, regardless of diet. However, an overall effect of inulin
consumption on increasing Pck1 expression was observed. Furthermore,
glucose 6-phosphatase (G6pc) expression was significantly increased in inulin
fed mice, regardless of exposure.
Magpix technology was utilized to quantify circulating metabolic hormone
levels at the end of the study (Figure 4.9). In cellulose-fed mice, PCB exposure
significantly reduced circulating leptin levels while no differences in leptin levels
were observed between the inulin-fed groups. Additionally, a significant
interaction of diet and exposure on leptin levels was observed. Furthermore,
inulin consumption had an overall significant effect of increasing circulating PYY
levels, while a PCB exposure had an overall reductive effect (Figure 4.9).
4.5

Discussion
Exposure to environmental pollutants, specifically dioxin-like pollutants, poses

numerous health threats to those exposed, including metabolic disruptions,
hepatic lipid accumulation, and gut dysbiosis. A common route of exposure to
dioxin-like pollutants is through contaminated foods and thus the gastrointestinal
system is exposed to the highest amounts of these pollutants. Utilizing a mouse
model of cardiometabolic disease, our lab has previously demonstrated that
exposure to PCB 126 induces gut dysbiosis, increases systemic and intestinal
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inflammation, accelerates atherosclerosis, and also induces metabolic
dysfunction [143, 181]. It is well understood that nutritional modulation of
pollutant toxicity effective means of reducing detrimental health effects of
pollutant exposure [61]. Therefore, in this study we sought to examine the role of
prebiotic nutritional intervention (i.e. inulin) on attenuating our previous
observations of PCB-induced disruption of gut microbiota and cardiometabolic
health. While analyses remain ongoing, the data currently demonstrate that
inulin feeding attenuated PCB-induced disruption of gut microbiota, host
metabolism, hepatic steatosis, and inflammation.
Dioxin-like pollutants are known for exerting various effects throughout the
body; one such effect being induction of significant loss of body weight, known as
wasting [219]. PCB exposure resulted in a significant reduction in body fat
percentage, while inulin-fed mice were protected from this effect. Interestingly,
throughout the study, inulin fed mice gained less weight than cellulose fed mice,
highlighting the potential adipose specific wasting induced by toxicant exposure
only observed in cellulose fed mice. Our lab has previously observed this
wasting effect upon exposure to PCB 126 in a mouse model of non-alcoholic
steatohepatitis (NASH) [42], indicating that the liver injury may play a role in this
wasting effect. Other studies have noted this effect of dioxin-like pollutants on
wasting but attributed it to reductions in food intake, which was observed in the
present study [220, 221]. Our observations of wasting in conjunction with no
changes in food intake are noteworthy, suggesting disruptions in energy
metabolism and storage. It is important to note that no observations of wasting
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were noted in our previous study (chapter three) using this model of
cardiometabolic disease, which may highlight a potential unique interplay
between the slightly elevated cellulose diet (i.e. 8% vs 5%) that altered the
toxicity and effects of PCB exposure. The observation of this effect is something
that calls for further examination in future studies.
When examining systemic host health, the liver is of utmost importance. The
liver is a vital organ for responsible for metabolism of both dietary constituents
and pollutants and is the second organ, following the gut, that comes in contact
with polychlorinated biphenyls. The liver has a unique and important relationship
with most organ systems of the body and recent research has substantiated
evidence for the interdependent relationship of the gut and liver, termed the “gutliver axis” as well as the liver and the heart, termed the “liver-heart axis” [222,
223]. In individuals with gut dysbiosis and/or cardiovascular disease, it is not
uncommon to observe liver pathologies such as nonalcoholic steatohepatitis
(NASH) or nonalcoholic fatty liver disease (NAFLD) [222, 223]. Importantly, it is
well accepted that exposure to persistent organic pollutants contributes to the
pathogenesis of NASH and NAFLD and thus has been recognized as its own
entity, “toxicant induced steatohepatitis” (TASH) [24]. Dioxin-like pollutants have
been demonstrated to not only increase hepatic lipid accumulation, the beginning
stages of TASH, but also to exacerbate non-alcoholic fatty liver disease, leading
to more advanced hepatic pathologies such as fibrosis [24, 42, 65]. Our lab has
previously studied this effect of pollutant exposure utilizing a mouse model in
which mice are fed a methionine-choline deficient (MCD) diet to induce NAFLD.

120

In aforementioned study, exposure to PCB 126 drastically exacerbated liver and
metabolic dysfunction induced by MCD feeding as evidenced by wasting,
increased systemic inflammatory markers, and presence of hepatic fibrosis [42].
Hepatic macrovesicular fat accumulation is what is most commonly observed
in obesity and NASH/NAFLD and is characterized by lipid droplets that
accumulate extrahepatocellularly. Microvesicular lipid accumulation is less
common and is characterized intrahepatocellular lipid accumulation, giving them
a foamy appearance and has been correlated with more advanced histology of
NAFLD [224]. Macrovesicular lipid accumulation was apparent in unexposed
cellulose fed mice, consistent with our previous studies and the progression of
cardiometabolic disease that is induced using the present mouse model.
However, in exposed cellulose fed mice, a shift from macrovesicular to
microvesicular lipid accumulation was observed, indicating a disruption in energy
metabolism and/or lipid transport. Importantly inulin fed mice were protected
from both macrovesicular and microvesicular hepatic lipid accumulation. This
reduction in hepatic lipid accumulation with inulin feeding is consistent across
numerous studies [225-228]. Importantly, in humans, it was observed that inulin
and inulin-propionate ester supplementation attenuate hepatic steatosis in
patients with NAFLD [225]. To our knowledge, the present study is the first to
examine inulin supplementation on dioxin-like pollutant exposure, but inulin
feeding has been studied in context of other xenobiotics. For example, it was
demonstrated that inulin supplementation reduced hepatic steatosis and
xenobiotic-induced (i.e. phenobarbital) liver injury in rats fed a high fat, high
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sucrose diet [228]. One mechanism by which inulin may attenuate hepatic
steatosis is hypothesized to be through the production of short chain fatty acids,
specifically propionate [229]. It has been observed that in hepatic steatosis,
propionate levels were significantly decreased in portal plasma [228, 230].
Importantly, propionate has been reported to inhibit fatty acid synthesis and thus
may provide one contributing mechanism by which inulin can attenuate hepatic
steatosis [231, 232]. However, it is important to note that the rate of utilization of
SCFA often make it difficult to truly capture levels present in portal or systemic
circulation and thus more mechanistic research is needed to truly understand the
role of inulin in attenuating hepatic steatosis.
Due to the liver being the central hub of metabolic processes, it is well
understood that hepatic inflammation and lipid accumulation can alter overall
metabolism, specially glucose metabolism [233, 234]. In the present study, PCB
exposure in cellulose fed mice resulted in glucose intolerance at both weeks 5
and 8 of the study, as evidenced by an increased area under the curve.
Importantly, inulin feeding was able to attenuate these disruptions in glucose
tolerance. PCB impairment in glucose tolerance has been documented by other
labs [162, 235]. To better understand the mechanisms behind these
improvements in glucose tolerance observed with inulin feeding, gene expression
of hepatic enzymes involved in glycolysis and gluconeogenesis were quantified.
Examining the rate limiting enzymes of glycolysis revealed that PCB exposure
significantly reduced pyruvate kinase (Pklr) and phosphofructokinase (Pfkl) gene
expression in mice fed cellulose, but not in mice fed inulin. There was also an
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insignificant decrease in glucokinase (Gck) expression in cellulose fed mice,
which was not present in inulin fed mice. To our knowledge, these PCB-induced
alterations in hepatic glycolytic enzymes have not been reported previously and
could play a role in an inability to properly metabolize glucose. We hypothesize
that these alterations were attenuated in inulin fed mice due to our observed
improvements hepatic lipid accumulation and inflammation, as these factors have
been demonstrated to contribute to metabolic dysfunction [233, 234].
The gastrointestinal tract is a key organ is tightly linked to various organ
systems including the liver, cardiovascular system, and neurological system [222,
223, 236]. The gut microbiota, defined as the trillions of bacteria residing within
the gastrointestinal tract can be strongly influenced by dietary and environmental
factors and may play a role in the detrimental health effects observed with PCB
exposure. A common measure of gut dysbiosis, or the abnormal distribution of
bacterial taxa, is alpha diversity. Alpha diversity calculates the richness and
evenness of a microbial sample and thus offers a means by which to broadly
compare the microbial composition of samples. Interestingly, there were no
significant effects of inulin feeding on alpha diversity. This finding has indeed
been observed in the literature previously [135]. Some reports indicate that inulin
feeding actually reduces alpha diversity, possibly due to the stimulation of a few
specific taxa that then predominate the microbiome [135, 237]. Diversity is a
good measure of looking at differences, but is not necessarily an indicator of
health, like some researchers like to report [238]. Therefore, diversity should be
treated as a starting point for further inquiry rather than as an outcome measure
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of “health”. A similar measure employed by researchers is to examine the
Firmicutes/Bacteroidetes ratio as this is observed to be increased in chronic
inflammatory diseases and metabolic syndrome. Contradictory to our previous
study, we observed no significant effect of exposure on this ratio, again
highlighting a discrepancy in the level of cellulose. However, mice fed inulin had
a lower Firmicutes/Bacteroidetes ratio, irrespective of exposure. This may
suggest a “healthier” microbial composition in our inulin mice. It is important to
note that with these comparisons being reliant on phyla level differences, it can
overgeneralize microbial composition and thus deeper taxonomic examination
should always be employed.
When looking at more specific microbial populations, interesting effects of
both diet and exposure were apparent. The levels of
Akkermansia/Verrucomicrobia observed in our study are notably elevated in all
groups, compared to a typical murine microbial signature [149]. This observation
was previously noted by our lab and we hypothesize that the high levels of
cholesterol in this model are influencing the growth of these bacteria [143].
Akkermansia muciniphila is commonly recognized as a beneficial bacterium,
consuming intestinal mucin and enhancing barrier function [88]. However,
researchers have noted that an overabundance of A. muciniphila can actually
exacerbate intestinal inflammation in mice [198]. Our consistent finding of
strikingly elevated levels of Akkermansia/Verrucomicrobia in this high cholesterol
model is a very important finding that should be pursued further to better
elucidate the specific mechanisms driving the large bloom of these bacteria.
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The genus Allobaculum appears to be sensitive to dietary interventions. A
significant diet effect of inulin increasing the level of this genus, irrespective of
exposure was observed. It has been demonstrated that Allobaculum decreases
under high fat feeding and that prebiotic (oligofructose) feeding is able to
increase the abundance of this genera [239]. This increase with prebiotic
treatment has been reproduced several times in the scientific literature [239-241].
Importantly, the genus Allobaculum has been associated with improved intestinal
barrier function and also resistance to the development of NAFLD [242].
Additionally, increases in Allobaculum have also been observed with metformin
treatment, a clinically effective drug used for the management of diabetes [243].
Therefore, our findings of increased Allobaculum abundance in all groups fed
inulin may be associated with our findings of reduced hepatic
steatosis/inflammation and improved glucose tolerance and metabolism.
Interestingly, PCB exposure increased the level of Coprococcus in mice fed
cellulose, but not in mice fed inulin. Microbial literature characterizing the genus
Coprococcus found an inability of the strains tested to ferment inulin, potentially
explaining why we saw a very low level of this genus in all mice fed inulin [244].
The increases observed in exposed mice fed cellulose could be due to a toxic
effect on other bacterial groups, allowing Coprococcus to proliferate. The genus
Coprococcus is a characterized butyrate producer, which is commonly regarded
as being beneficial for intestinal health [245]. However, in chapter two, PCB
exposure in fecal cell suspensions did not impede butyrate production, indicating
that butyrate producing bacteria may be unsusceptible to PCB toxicity.
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With regards to the common probiotic bacteria Lactobacillus and
Bifidobacterium, inulin feeding significantly increased levels of these bacteria,
irrespective of exposure. However, exposure to PCB 126 in inulin fed mice
further increased the levels of these bacteria. This may be due to a toxic effect of
PCBs on other bacterial populations, allowing the proliferation of Bifidobacterium
and Lactobacillus. Inulin feeding is well accepted to stimulate Bifidobacterium
and Lactobacillus. For example, in humans, inulin supplementation has been
demonstrated to increase Bifidobacterium and Lactobacillus following 14 days of
supplementation [246]. Furthermore, in a randomized, double-blind placebocontrolled crossover study, increases in Bifidobacterium and Lactobacillus were
observed in healthy adults administered long-chain inulin for 14 days [247].
Additionally, studies found that these genera were not only increased following
prebiotic supplementation, but that this increase was associated with
improvements in metabolic health and glucose metabolism [203, 204].
Bifidobacterium and Lactobacillus exhibit very little proteolytic activity and are
predominantly saccrolytic, which some argue, is beneficial [127]. Along these
lines, in inulin fed mice reductions in circulating p-cresol were observed (data not
shown), product of microbial proteolytic fermentation. This suggests a reduced
capacity for proteolytic fermentation in inulin-fed mice, which may confer a health
benefit to the host [127]. Overall, inulin exhibited pronounced effects on the
microbiota which may contribute to our observations of improved systemic host
health and protection against pollutant toxicity.
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The intestinal environment, in addition to harboring important microbial
populations, functions in hormonal regulation of appetite and metabolism [248].
Quantification of circulating metabolic hormone levels revealed differential effects
of diet and exposure. Peptide YY (PYY) is an enteroendocrine peptide that is
secreted by intestinal L cells and aids in the regulation of body weight [249].
PYY is known as an anorexigenic hormone, and signals to reduce appetite.
Interestingly, PYY levels were overall higher in inulin fed mice compared to
cellulose fed mice and exposure exhibited an overall reductive effect on PYY. It
is well accepted that dietary fiber consumption increases PYY secretion and
induces satiety [249]. Furthermore, it has been observed that short chain fatty
acid (SCFA) production from microbial fermentation of fiber can contribute to the
regulation of PYY secretion [250, 251]. The overall exposure-induced reductions
in PYY levels we observe could suggest that SCFA levels are modified or that
there is disruption in intestinal L cell health. We will further explore this potential
mechanism through quantification of SCFA levels in the plasma and feces and
examination gene expression coding for these metabolic hormones within the
ileum.
Leptin, a well characterized adipokine, contributes to regulation of energy
balance through inhibition of hunger and modulation of glucose and fatty acid
metabolism [252]. Serum levels of leptin were significantly reduced in cellulosefed exposed mice. This finding has been reported previously in the literature with
exposure to persistent organic pollutants. For example, in the Yusho cohort, a
Japanese population of dioxin-exposed individuals, a significant reduction in
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serum leptin levels was observed [253]. Interestingly, there are several studies
demonstrating that leptin exerts an insulin-like effect [252]. For example, leptin
administration has been demonstrated to contribute to normoglycemia and
improving insulin responses in response to streptozotocin-induced diabetes
[254]. Therefore, detriments to leptin levels in cellulose-fed exposed mice could
contribute to our observed disruptions in glucose homeostasis. Our observation
of a reduced level of leptin is not surprising due to the reduced level of body fat
observed in our cellulose-fed exposed mice, however this finding highlights a role
of the adipose tissue in PCB toxicity and protection with inulin consumption that
needs to be further explored.
Aside from microbial modulation and hormone modulation, another potential
mechanism of inulin-induced improvements host health and metabolism is
reduction in metabolites associated with cardiovascular disease. In the liver, a
significant increase in ceramide species, including 18:1/20:0 and 18:1/24:1 was
observed in exposed mice fed cellulose, while mice fed inulin were protected
from this increase. It has recently been accepted that ceramides are a biomarker
of cardiovascular disease risk, increasing inflammation, reactive oxygen species,
and causing cellular dysfunction [255]. Ceramides are not only linked with
cardiovascular disease but also with NAFLD [256]. For example, an increased
serum level of ceramides was observed in obese children with NAFLD [257]. It
has also been demonstrated that modulation of ceramide production in NAFLD
helps reduce the progress of atherosclerosis, highlighting the strong tie between
the hepatic and cardiovascular systems [258]. In support of our ceramide
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concentrations in the liver, a PCB-induced decrease in Mttp was observed in
cellulose fed mice and attenuated in inulin-fed mice. Mttp is a critical protein
involved in the transfer of ceramides from the liver to the plasma [259].
Consistent with these data, PCB-induced increases in ceramides within the
plasma were not observed. (data not shown). Our observations of increases in
hepatic ceramides along with presence of hepatic steatosis and inflammation are
noteworthy in that they are major risk factors of cardiometabolic disease.
Furthermore, to our knowledge this is the first study demonstrating that exposure
to PCBs increases ceramide production, highlighting a new mechanism of PCB
toxicity to be explored in future studies.
The present study adds significantly to the growing body of literature
demonstrating the beneficial effects of nutrition on combatting pollutant toxicity,
however there are a few limitations to note that should be addressed in
subsequent experiments. Firstly, it is recommended that humans consume 14g
of fiber per 1000 calories [218]. The traditional level of fiber in purified diets and
our previous study is 5%, equating to 12g per 1000 calories. The diets in the
current study both had fiber present at the 8% level, equating to 21g per 1000
calories. Therefore, the cellulose and inulin diets used in the present study can
be considered high fiber diets and thus future studies should examine all levels of
fiber intake (i.e. low, adequate, high) to fully understand the interactions between
fiber consumption and pollutant exposure. It is also important to note that the
present study only utilizes male mice. Future studies should employ male and
female mice as there are various differences including that of specific aspects of
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metabolism and gut microbiota populations. Finally, there are still measurements
to be made to further elucidate the mechanisms driving the observed phenotypes
in this study. To better understand the role of the microbiota in the inulin-driven
protection against PCB toxicity we will quantify SCFA levels in the feces and
plasma. As discussed in chapter one, SCFA levels are sensed by specific Gprotein coupled receptors (GPRs), GPR41 and GPR43, which are involved in
numerous systemic processes including the regulation of glucose and lipid
metabolism [86, 91]. Therefore, quantification of SCFA is important to follow up
on due to our present observed effects of PCBs on glucose metabolism and lipid
accumulation as well as the PCB effects on SCFA production in observed both
chapter two and chapter three. Additionally, quantification of fecal, plasma, and
hepatic levels of PCBs will be conducted to examine if cellulose or inulin drive
different deposition profiles of these pollutants, thereby influencing their toxicity.
Inulin has been well demonstrated to reduce cholesterol and improve lipid
profiles in humans [127]. Therefore, quantification of cholesterol and
triglycerides both in the liver and in plasma will also be conducted to observe if a
reduction in these could be a potential mechanism by which inulin attenuates
inflammation and hepatic steatosis. Finally and importantly, atherosclerotic
lesions will be quantified to examine if the observed protective effects of inulin
translate to an attenuated atherosclerotic risk.
Overall, the data presented demonstrates that consumption of the prebiotic
inulin is capable of attenuating PCB 126-induced disruption of gut microbial
population, host metabolism and systemic inflammation. Importantly, the
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elevated level of fiber in the control group compared to our previous study (8%
cellulose vs. 5% cellulose) may confer metabolic alterations and may also impact
the toxicity of PCB 126, which is a parameter that needs further examination.
We hypothesize that through alterations in gut microbial populations and
microbial metabolite production, that inulin is able to reduce cardiometabolic
disease risk. This study is important in that increasing dietary inulin consumption
is an easily attainable means for all human populations and poses little to no risk
for health. More research is needed to elucidate the direct mechanisms of
attenuations in PCB toxicity induced by inulin feeding.
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Table 4.1. Diet Formulation

Protein
Carbohydrate
Fat
Total
Kcal/gm

8% Cellulose
gm
18.6
64.9
4.1
3.71

8% Inulin

kcal
20.0
70.0
10.0
100.0

gm
19.2
64.0
4.2
3.83

kcal
20.0
70.0
10.0
100.0

Ingredient
Casein, Lactic
L-Cystine

200
3

800
12

200
3

800
12

Corn Starch
Maltodextrin 10
Sucrose

375
125
200

1500
500
800

343.1
125
200

1372.4
500
800

Cellulose
Inulin

87.5
0

0
0

0
84.8

0
127.2

Soybean Oil
Cocoa Butter

25
20

225
180

25
20

225
180

Mineral Mix S10021
Dicalcium Phosphate
Calcium Carbonate
Potassium Citrate

10
13
5.5
16.5

0
0
0
0

10
13
5.5
16.5

0
0
0
0

Vitamin Mix V10001
Choline Bitartrate

10
2

40
0

10
2

40
0

Cholesterol

1.6

0

1.6

0

Total

1094.10

4057

1059.50

1094.10
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Table 4.2. Genera level differences in gut microbial populations
Cellulose +
Vehicle
371.9 + 67.0

Cellulose +
PCB 126
229.8 + 25.8

Inulin +
Vehicle
527.4 + 25.6*

Inulin +
PCB 126
709.4 + 73.1*‡

Bifidobacterium

12.1 + 3.0

24.1 + 9.7

597.2 + 136.7*

Lactobacillus

19.8 + 6.7

13.1 + 4.8

152.1 + 41.9*

1432.5 +
196.6*‡
403.1 + 95.9*‡

Lactococcus

219.6 + 42.7

212.1 + 72.4

123.7 + 19.5

161.3 + 31.3

Turicibacter

38.5 + 10.4

11.7 + 3.0‡

3.6 + 0.8*

3.9 + 1.3

Clostridium

18.4 + 4.3

19.6 + 2.9

4.2 + 1.4*

2.5 + 0.7*

Dehalobacterium

74.2 + 8.8

43.9 + 7.7

Other

Coprococcus

302.0 + 38.0

88.3 + 23.2

46.3 + 7.9

863.6 +

234.4‡

61.9 + 21.0*

108.7 + 23.5

13.4‡

21.3 + 8.2*

16.4 + 4.7*

Dorea

126.0 + 14.7

41.2 +

[Ruminococcus]

462.0 + 58.0

560.4 + 35.1

129.0 + 16.3

908.0 + 193.5‡

rc4-4

1405.0 +
409.1
2755.2 +
352.2
727.4 + 63.9

0.8 + 0.5‡

211.0 + 96.1*

249.0 + 44.9*

1784.1 +
214.2‡
861.8 + 85.1

1251.0 + 215.7*

1115.0 + 118.4

545.6 + 75.5

340.8 + 58.4*

5064.8 +
1593.3
66.9 + 14.2

2007.5 + 565.8
82.8 + 16.1

12019.1 +
2319.5*
1.0 + 0.5*

14419.7 +
1895.7*
2.8 + 1.0*

772.2 +
295.0
2129.3 +
811.1
37403.2 +
2784.1

1092.1 + 178.2

1585.3 + 135.0*

993.7 + 133.1

6.2 + 1.4‡

2.6 + 0.8*

7.6 + 3.6

43081.5 +
3849.6

21070.1 +
2235.5*

31416.8 +
2044.5*

Oscillospira
Ruminococcus
Allobaculum
Coprobacillus
Sutterella
Desulfovibrio
Akkermansia

*indicates a significant difference compared to cellulose diet; ‡ indicates a significant difference compared to vehicle of
same diet (n=10). Data analyzed by two-way ANOVA with post hoc comparisons of the means.
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Figure 4.1. Inulin consumption protects against PCB-induced wasting.

Figure 4.1. Inulin consumption protects against PCB-induced wasting.
Male Ldlr-/- mice were fed an atherogenic diet containing 8% cellulose or 8%
inulin for 12 weeks and exposed to PCB 126 (1µmol/kg) or vehicle at weeks 2
and 4. A. Weight change (g) from baseline to the end of the study. Cellulose fed
mice exposed to PCBs had significantly greater weight gain than exposed inulin
mice. B. Fat composition quantified using EchoMRI. PCB exposure reduced
body fat percentage in the cellulose-fed group, which was attenuated by inulin
consumption. C. Average energy intake (kcals) per day. Data are presented as
mean + S.E.M (n=10 per group). Statistical significance is denoted by * (p<0.05).
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Figure 4.2. Inulin attenuates PCB-disruption in glucose tolerance

Figure 4.2. Inulin attenuates PCB-disruption in glucose tolerance. Male
Ldlr-/- mice were fed an atherogenic diet containing 8% cellulose or 8% inulin for
12 weeks and exposed to PCB 126 (1µmol/kg) or vehicle at weeks 2 and 4. A.
Fasting blood glucose and glucose tolerance testing at week 5. PCB exposure
increased fasting blood glucose levels in cellulose fed mice and not in inulin fed
mice. Cellulose fed mice exposed to PCBs displayed a greater area under the
curve (AUC) compared to exposed inulin fed mice. B. Fasting blood glucose
and glucose tolerance testing at week 8. No differences were observed in fasting
blood glucose. The effects of PCBs and diet on AUC remained significant at 8
weeks. Data are presented as mean + S.E.M (n=10 per group). Statistical
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significance is denoted by * (p<0.05). For glucose curves, ‡ indicates a
significant difference between “Cellulose + PCB” and “Inulin + PCB” and *
indicates a significant difference between “Cellulose + Vehicle” and “Cellulose +
PCB”.
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Figure 4.3. Inulin consumption reduces PCB-induced hepatic lipid accumulation

Figure 4.3. Inulin consumption reduces PCB-induced hepatic lipid
accumulation. Male Ldlr-/- mice were fed an atherogenic diet containing 8%
cellulose or 8% inulin for 12 weeks and exposed to PCB 126 (1µmol/kg) or
vehicle at weeks 2 and 4. A. Liver weight/body weight ratio. PCB exposure
increased liver weight in cellulose fed mice, which was attenuated by inulin
feeding. B. Hematoxylin and eosin staining of hepatic tissue sections. Increases
in microvescicular fat accumulation was evident in PCB exposed mice fed
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cellulose, which appeared to be attenuated by inulin consumption. Inulin feeding
also had an overall effect of reducing macrovesicular fat accumulation. Data are
presented as mean + S.E.M (n=10 per group). Statistical significance is denoted
by * (p<0.05).
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Figure 4.4. Inulin feeding drives shifts in microbial composition at the phyla level

Figure 4.4. Inulin feeding drives shifts in microbial composition at the phyla
level. Male Ldlr-/- mice were fed an atherogenic diet containing 8% cellulose or
8% inulin for 12 weeks and exposed to PCB 126 (1µmol/kg) or vehicle at weeks
2 and 4. Cecum contents were also collected at the conclusion of the study.
16S rRNA sequencing was conducted and data was analyzed using QIIME. A.
Differences in the phyla level composition of the gut microbiota. Inulin feeding
decreased Verrucomicrobia and increased Actinobacteria. *indicates a
significant difference compared to cellulose diet and ‡ indicates a significant
difference compared to vehicle of same diet. Data are presented as relative
abundances. B. Firmicutes/Bacteroidetes ratio. Inulin feeding had a significant
overall effect of lowering the Firmicutes/Bacteroidetes ratio. C. Alpha diversity
(Shannon Diversity Index). PCB exposure had a significant overall effect of
lowering alpha diversity. Data are presented as mean + S.E.M (n=10 per group;
two-way ANOVA with post hoc comparisons of the means). Statistical
significance is denoted by * (p<0.05).
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Figure 4.5. Inulin and PCB exposure modulate gut microbial populations

Figure 4.5. Inulin and PCB exposure modulate gut microbial populations.
Male Ldlr-/- mice were fed an atherogenic diet containing 8% cellulose or 8%
inulin for 12 weeks and exposed to PCB 126 (1µmol/kg) or vehicle at weeks 2
and 4. Cecum contents were also collected at the conclusion of the study. 16S
rRNA sequencing was conducted and data was analyzed using QIIME. PCB
exposure increased Coprococcus abundance in cellulose fed mice, which was
attenuated in mice fed inulin. PCB exposure increased the level of Akkermansia
irrespective of diet. Irrespective of exposure, inulin feeding increased levels of
Bifidobacterium, Lactobacillus, and Allobaculum compared to cellulose feeding.
Data are presented as mean + S.E.M (n=10 per group; two-way ANOVA with
post hoc comparisons of the means). Statistical significance is denoted by *
(p<0.05)
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Figure 4.6. Inulin attenuates PCB-induced changes in hepatic inflammatory and
detoxification markers

Figure 4.6. Inulin attenuates PCB-induced changes in hepatic inflammatory
and detoxification markers. Male Ldlr-/- mice were fed an atherogenic diet
containing 8% cellulose or 8% inulin for 12 weeks and exposed to PCB 126
(1µmol/kg) or vehicle at weeks 2 and 4. Liver samples were collected at the
conclusion of the study. mRNA units were determined using the relative
quantification method (ΔΔCT), normalized to control values. 18S was used as the
housekeeping gene for all hepatic gene expression quantifications. A. mRNA
quantification of hepatic markers of inflammation. PCB exposure increased
expression of tumor necrosis factor alpha (Tnfα) and lipopolysaccharide binding
protein (Lbp), which was attenuated by inulin consumption. B. mRNA
quantification of hepatic markers of xenobiotic detoxification. PCB-induced
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increases in cytochrome p450 (Cyp1a1) expression was lower in inulin fed mice
compared to cellulose fed mice. Multidrug resistance protein (Mrp2) expression
was lower in exposed inulin fed mice compared to exposed cellulose fed mice.
Data are presented as mean + S.E.M (n=10 per group). Statistical significance is
denoted by * (p<0.05).
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Figure 4.7. Inulin attenuates PCB-induced increase in hepatic ceramides

Figure 4.8. Inulin attenuates PCB-induced increase in hepatic ceramides.
Male Ldlr-/- mice were fed an atherogenic diet containing 8% cellulose or 8%
inulin for 12 weeks and exposed to PCB 126 (1µmol/kg) or vehicle at weeks 2
and 4. Liver samples were collected at the conclusion of the study. A. Hepatic
quantification of ceramide levels via lipidomics. PCB exposure increased hepatic
ceramide species 18:1/20:0 and 18:1/24:1 and total ceramides in cellulose fed
mice but not inulin fed mice. B. mRNA quantification of microsomal triglyceride
transport protein (Mttp). In mice fed cellulose, PCB exposure decreased
expression of Mttp, which was attenuated in exposed mice fed inulin. mRNA
units were determined using the relative quantification method (ΔΔCT),
normalized to control values. 18S was used as the housekeeping gene for all
hepatic gene expression quantifications. Data are presented as mean + S.E.M
(n=10 per group). Statistical significance is denoted by * (p<0.05).
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Figure 4.8. PCB disruption of glucose metabolism is attenuated by inulin

Figure 4.8. PCB disruption of glucose metabolism is attenuated by inulin.
Male Ldlr-/- mice were fed an atherogenic diet containing 8% cellulose or 8%
inulin for 12 weeks and exposed to PCB 126 (1µmol/kg) or vehicle at weeks 2
and 4. Liver samples were collected at the conclusion of the study. mRNA units
were determined using the relative quantification method (ΔΔCT), normalized to
control values. 18S was used as the housekeeping gene for all hepatic gene
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expression quantifications. PCB exposure reduced expression of rate limiting
glycolytic enzymes glucokinase/hexokinase (Gck) and pyruvate kinase (Pklr),
which was not observed in inulin fed mice. Overall, inulin feeding increased
gluconeogenic enzyme expression including PEP carboxykinase (Pck1) and
glucose-6-phosphate (G6pc) irrespective of exposure. Data are presented as
mean + S.E.M (n=10 per group). Statistical significance is denoted by * (p<0.05).
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Figure 4.9. PCB 126 and inulin alter circulating metabolic hormones

Figure 4.9. PCB 126 and inulin alter circulating metabolic hormones. Male
Ldlr-/- mice were fed an atherogenic diet containing 8% cellulose or 8% inulin for
12 weeks and exposed to PCB 126 (1µmol/kg) or vehicle at weeks 2 and 4.
Circulating hormones related to energy metabolism were quantified via Magpix
technology. PCB exposure reduced leptin levels in cellulose fed mice but not in
inulin fed mice. An overall effect of inulin consumption on increasing PYY levels
was observed while a reductive effect of PCB exposure on PYY was noted. Data
are presented as mean + S.E.M (n=10 per group). Statistical significance is
denoted by * (p<0.05).
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Chapter 5
5.1

Overall Discussion

Discussion

5.1.1 Summary
The research presented in this dissertation discusses novel observations into
the effects of polychlorinated biphenyl (PCB) exposure on the gut microbiota and
how this impacts overall host health. Our primary goal is to find means by which
to decrease the negative health effects of pollutant exposure; thus, this
dissertation provides insight into a novel avenue of nutritional mediation in
pollutant exposures, the consumption of prebiotics (i.e. dietary fiber). The gut
microbiota is influenced by a variety of factors including dietary intake as well as
environmental exposures and has been implicated in the development of several
diseases, including cardiovascular disease and diabetes. We demonstrated that
PCB exposure detrimentally impacts the gut microbiota, specifically by
decreasing diversity, increasing the inflammatory-associated Firmicutes to
Bacteroidetes ratio, and decreasing specific beneficial bacterial genera.
Furthermore, we elucidated that PCB exposure directly impacts certain bacteria
through membrane disruption, leading to an overall change in fermentation acid
production in the host and thus increasing the risk of metabolic diseases. Finally,
we demonstrated the role of prebiotic (i.e. inulin) consumption in attenuating
PCB-induced microbial and metabolic dysfunction.
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5.1.2 PCB 126 disrupts microbial fermentation of a prebiotic substrate
There is evidence that exposure to environmental pollutants can impact gut
microbial populations but the mechanisms and specific bacterial populations
affected remains unknown. It has been shown that pollutants including 2,3,7,8
tetrochlorodibenzofuran, benzo[a]pyrene, and PCBs can alter gut microbial
pollutions as well as induce intestinal inflammation [18, 19, 178, 185, 193].
However, these studies did not address the direct impact of these various
pollutants on the bacteria themselves. Conversely, research on environmental
bacterial populations and pollutants has substantiated that there is indeed an
interplay between pollutants and bacterial populations [157, 158]. For example,
research on the ability of particular bacterial populations to degrade pollutants
such as polyaromatic hydrocarbons has been appreciably studied and has
yielded promising results [260]. Due to the vast presence of PCBs in the
environment, past research has examined their effects on soil bacterial
populations and determined that there was no convincing evidence that PCBs
exert genotoxicity but instead may have effects on the bacterial cell membrane
[157, 158]. While these findings provide some insight into the interactions
between pollutants and bacteria, it is important to note that the bacteria found in
soil environments are primarily aerobes while the bacteria residing in the
mammalian gut are primarily anaerobes, which may cause differences in
metabolism and response to pollutant exposure. The work described in chapter
two of this dissertation attempted to address this gap in the literature by studying
the direct effects of PCB exposure on isolated gut microbial populations.
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Using an inulin-fermenting isolate from murine feces, we determined that as
concentrations of PCB 126 increased, there was a significant impediment on
bacterial viability. To determine if PCBs were membrane disruptive in an
anaerobic gut microbe, we quantified intracellular potassium and confirmed our
observed reductions in viability to be due to perturbations in the bacterial cell
membrane. This is important in that this is the first instance in which it has been
demonstrated that PCBs can exert direct toxic effects on specific gut microbial
populations. Furthermore, our findings that these disruptions translated to overall
alterations in fermentation acid production from a mixed fecal microbial sample
demonstrate the impact that PCB disruption of gut microbiota can have on the
overall host. Importantly, upon increasing the prebiotic inulin substrate, the
bacteria were able to overcome the disruptions in fermentation acid production.
Fermentation acid or short chain fatty acid (SCFA) production has been more
recently understood to influence numerous properties that affect host health [84,
91]. The primary SCFAs acetate, propionate, and butyrate all exert differential
effects throughout the human body. Butyrate functions primarily within the
intestine, serving as a preferential energy source for colonocytes and has been
associated with improved intestinal health [245]. Acetate and propionate exert
functions within the liver and peripherally, modulating glucose and lipid
metabolism [85]. Therefore, PCB-induced disruptions in gut microbial production
of SCFAs could be responsible for the observed disruptions in hepatic
metabolism, glucose tolerance, and intestinal inflammation. Overall, our findings
of PCB-induced disruption of gut microbial fermentation, alleviated by increased
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prebiotic substrate, highlights that the bacteria that can proliferate at a higher
level of inulin are likely not sensitive to PCB exposure. Therefore, focusing our
research on elucidating and targeting the effected populations could be greatly
beneficial for host health.

5.1.3 Exposure to PCB 126 disrupts gut microbial and metabolic homeostasis
Dioxin-like pollutants are found in many animal food products and thus human
exposure is initiated upon consumption, with the first impact being on the
gastrointestinal tract. Thus, in work described within chapter three of this
dissertation we attempted to address the role of the gut in the PCB-toxicity. We
hypothesized that PCB toxicity initiated in the gut and influenced the
development of peripheral inflammation and disease.
It has been well established that cardiometabolic disease is strongly linked to
gastrointestinal health and the gut microbiome. It has been demonstrated that
individuals with cardiometabolic diseases possess unique microbial signatures,
suggesting a potential interplay of the microbiota in the pathogenesis of these
diseases. For example, individuals with atherosclerosis and type 2 diabetes
exhibit increases in Firmicutes and reductions in Bacteroidetes [261].
Additionally, an epidemiological study investigating cardiovascular health
indicated that stool populations of Prevotella 2 and Prevotella 7 were associated
with an increased lifetime risk for cardiovascular disease [262]. Interestingly,
treatment with antibiotics was able to lower circulating levels of TMAO, a
biomarker that has been identified as a risk factor for cardiovascular disease.
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Furthermore, these researchers demonstrated that antibiotic-induced reduction in
TMAO correlated with a decrease in aortic plaque and a decreased number of
macrophages within the plaque [104, 263]. These data highlight the critical
interplay of the gut microbiota in the pathogenesis of disease.
It has also been well established that dioxin-like pollutant exposure can
increase the risk of cardiovascular disease developments [38]. Recently, our lab
demonstrated that exposure to PCB 126 increases systemic inflammation and
accelerates the development of atherosclerosis in a mouse model of
cardiometabolic disease [181]. To expand on this previous finding and to
elucidate the effect of PCB exposure on the gut microbiota and how this may
play a role in cardiometabolic disease, LDLr-\- mice were fed an atherogenic diet
and exposed to a low dose of PCB 126 and parameters of metabolic and
microbial health were analyzed. We found that PCB exposure induced disruption
of gut microbial populations, primarily in the cecum contents. PCB exposure
reduced gut microbial diversity and increased the Firmicutes to Bacteroidetes
ratio, both of which are observed in chronic inflammatory conditions and
cardiometabolic diseases. This finding is consistent with other studies
demonstrating that pollutant exposure, specifically dioxin, results in increases in
the Firmicutes to Bacteroidetes ratio, which correlated with liver and immune
toxicity [193].
We also observed PCB-induced reduction of Oscillospira, Bifidobacterium,
and Lactobacillus, all of which have been correlated with positive health
outcomes for the host. Importantly, we observed a significant positive correlation
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between circulating levels of glucagon like peptide-1 (GLP-1) and
Bifidobacterium that was dependent on PCB exposure. This finding is important
due to the role of GLP-1 on modulating glucose metabolism through control of
insulin secretion as well as studies demonstrating that Bifidobacterium
supplementation can improve insulin sensitivity [206]. Along with this, our
observations of hyperinsulinemia in the absence of glucose intolerance in PCBtreated mice suggest a prediabetic phenotype. Other labs have observed
impairments in glucose tolerance in response to PCB-exposure, but our finding is
the first to highlight that these impairments may be linked to gut microbial
disruption.
Additionally, we conducted hepatic metabolomics to examine the impact of
PCB exposure on metabolism. We observed that PCB exposure reduced
glycolytic intermediates, increased fatty acid metabolism intermediates, and
induced alterations in metabolites that have been demonstrated to be influenced
by host-microbial interactions (e.g. N-acetylphenylalanine, dimethylglycine). We
hypothesized that our observed shift away from carbohydrate metabolism to fatty
acid metabolism could be a consequence of hyperinsulinemia. Due to these
findings of altered liver metabolites, the subsequent study (chapter four) focuses
on following up on this finding and examining hepatic metabolism and health
more thoroughly.
Overall, we hypothesize that our findings of increased inflammation, metabolic
disruption, and gut dysbiosis in PCB-exposed mice may occur concurrently and
have a feed-forward effect on each other. These findings reveal a novel
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opportunity for intestinally-targeted nutritional intervention to attenuate the
detrimental effects of PCBs on both gut dysbiosis and overall host health.

5.1.4 Inulin consumption reduces gut and systemic toxicity of PCB 126
It is well understood that a healthful diet, rich in fruits, vegetables, and foods
high in bioactive compounds, can confer a benefit on cardiometabolic disease
risk and reduction [218]. Our lab has shown previously that flavonoids and
polyphenols can be protective against PCB-related endothelial cell dysfunction, a
beginning pathological step in the development of atherosclerosis [264].
Furthermore, we have also demonstrated that consumption of bioactive
components can reduce pollutant-induced oxidative stress, which is a known
player in the development of metabolic dysfunction [73]. In work described within
chapter three of this dissertation, we attempted to expand the scope of nutritional
modulation of PCB toxicity to parameters that are well known to have an
influence on gut health and the gut microbiota, specifically the prebiotic fiber
inulin. Inulin is an inulin type fructan found in many vegetables (e.g. onions,
leeks, and chicory root) and is composed of chains of fructosyl groups linked by
(2-1) glycosydic bonds, terminated with an -D(1-2)-glucopyranoside ring group
on the reducing end [128, 134]. Inulin is added to many food products to
increase fiber content and provide sweetness without adding significant caloric
content. It has been found that in the US, most individuals fall below the
recommendations of 25g or 38g of fiber per day for women and men,
respectively [113, 125]. This provides an important avenue for intervention due
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to fiber’s known benefits on gastrointestinal health, cardiometabolic health, and
weight management. Importantly, PCB exposure has been demonstrated to
have detrimental impacts on all of these health conditions, and thus consumption
of a diet rich in fiber is a feasible means by which to address and attenuate the
negative effects of pollutant exposure. In the work described within chapter four
of this dissertation we attempted to elucidate the role of inulin in modulating
pollutant toxicity by supplementing mice with a diet high in inulin and
subsequently exposing them to low levels of PCB 126.
We found that exposure to PCB 126 induced significant fat mass loss in
cellulose fed mice. Interestingly, this wasting was attenuated in exposed mice
fed inulin. The lipophilic nature of dioxin-like pollutants such as PCBs cause
them to accumulate in adipose tissue where they can induce inflammation and
cause disruption in adipocyte metabolism [158]. Furthermore, research has
shown that if PCB exposed obese mice undergo weight loss, the PCBs are
released into circulation where they can exacerbate inflammation and diabetic
symptoms, indicating a somewhat protective role of adipose tissue in preventing
pollutant toxicity in other organs [162]. We hypothesize that the wasting induced
by PCB exposure resulted in greater circulating levels of these pollutants, which
could contribute to disruptions in host health and metabolism. We intend to
follow up on levels of PCBs both in circulation and within the feces to address
this hypothesis.
While cellulose fed mice exposed to PCBs exhibited a lower percent body fat,
their livers were actually heavier and harbored a greater amount of
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microvesicular fat. It is well accepted and understood that hepatic steatosis can
contribute to metabolic disruptions and inflammation [233, 234]. If our hypothesis
of greater circulating levels of PCBs in cellulose fed mice is correct, their
participation in enterohepatic circulation could exacerbate the effects on the
hepatic and gastrointestinal systems. Consistent with our observations of
hepatic steatosis, PCB-exposed mice exhibited higher levels of inflammatory
markers and inulin feeding was able to attenuate these increases. Furthermore,
we observed that PCB exposure altered expression of key glycolytic and
gluconeogenic enzymes and that inulin feeding was able to blunt these effects,
suggesting a potential mechanism for our observations in disrupted glucose
tolerance with PCB exposure and amelioration by inulin.
In chapter three, we established that PCBs induced alterations in the gut
microbiota and that some of these alterations correlated with disruptions in
metabolic markers. Due to inulin’s high prebiotic capacity, we hypothesized that
inulin feeding would attenuate PCB-induced disruptions in the microbiota and
that these alterations would lead to overall improved host health. Indeed, we
observed several effects of inulin feeding on microbial populations. Inulin is
known to be a bifidogenic compound, stimulating the growth of Bifidobacterium
[133]. As expected, we observed significant increases in the levels of
Bifidobacterium in inulin fed mice, irrespective of exposure. Interestingly,
exposure to PCB 126 in inulin fed mice further increased the levels of these
bacteria. We hypothesize that this finding is due to a toxic effect of PCBs on
other bacterial populations, thereby allowing for the proliferation of
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Bifidobacterium. Furthermore, we also observed that inulin fed mice exhibited a
lower Firmicutes:Bacteroidetes ratio, irrespective of exposure, suggesting a
“healthier” microbial signature. Inulin appeared to exert a stronger effect on
influencing microbial populations than did PCB exposure, which could be
expected due to inulin’s known prebiotic capabilities.
Due to our more thorough exploration of hepatic effects of pollutant exposure
in this study, we discovered an avenue that has not previously been explored by
our lab. In chapter four, we identified that hepatic ceramide levels were
increased with PCB exposure. This is important in that ceramides have been
more recently accepted as a biomarker for cardiometabolic disease risk [255].
Furthermore, we observed that inulin feeding was able to attenuate this increase.
We also determined that hepatic microsomal triglyceride transfer protein (Mttp)
expression was reduced with PCB exposure, which has been demonstrated to
function in ceramide transport out of the liver [259]. Consistent with our findings,
the level of Mttp expression was restored with inulin feeding, indicating a
potential mechanism that needs to be further explored. To our knowledge, this is
the first instance in which ceramide levels were examined with PCB exposure
and thus this finding opens up a new avenue of exploration into PCB-toxicity.
When comparing the toxicity and effects of PCB exposure in the studies
described in chapter three and chapter four, we observed discrepancies that
should be noted. The only difference between the models used in these
chapters is the level of fiber. In chapter three, the level of fiber in the control
group was 5% from microcrystalline cellulose, whereas in chapter four, the level
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of fiber in the control groups (cellulose) were 8% from microcrystalline cellulose.
While a higher level of fiber consumption is believed to be more beneficial to host
health, in chapter four we actually observed greater toxicity of PCB exposure
despite a higher level of fiber. When comparing the exposed groups in both
studies, we observed exacerbation of wasting and glucose tolerance in mice fed
8% cellulose but this was not observed in mice fed 5% cellulose. Interestingly,
the microbial effects of PCB exposure in cellulose fed were not as apparent in
the study described in chapter four compared to our previous findings in chapter
three. Quantification of PCB levels in the feces and plasma is an ongoing
analysis to better compare the body burden of PCBs between these two studies.
Overall, we observed a discrepancy between the level of cellulose fiber (5% vs
8%) that may influence the toxicity of PCBs and will be followed up on in future
studies.

5.2

Future directions and conclusions
The levels of environmental pollutants throughout the world continue to rise,

despite numerous efforts towards reduction [2, 3]. Because pollutant exposure is
mostly unavoidable, it is important to not only understand its impacts on human
health, but also to elucidate means to provide protection against and/or
ameliorate symptoms of exposure. One of the primary routes of exposure to
lipophilic pollutants such as PCBs is through the ingestion of contaminated food
products (e.g. fatty fish, meat, and dairy) and thus, focusing on the
gastrointestinal tract is critical to understand the whole scope of PCB toxicity [2].
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There are numerous future directions that can be pursued related to the work
described within this dissertation. Firstly, to elucidate role of the microbiota in the
influence of pollutant-induced disease, studies utilizing mouse models in which
the microbiota has been manipulated could provide critical information. The
research described in chapter two and three of this dissertation highlighted that
PCB exposure can impact viability and fermentative properties of specific gut
microbial populations and can do so through membrane disruptive mechanisms.
However, it is still unknown what proportion of the impacts on the microbiota we
observed are from direct disruption of specific bacteria or from indirect disruption
through host inflammation and disease progression. Therefore, utilizing means
of eliminating, reducing, or shifting gut microbial populations could be helpful in
elucidating their role in PCB toxicity. One such means to do so would be the use
of broad-spectrum antibiotic treated mice to eradicate a large proportion of the
microbiota. Antibiotic treated mice have been used for studies investigating the
role of eradicating specific groups of bacteria and for investigating the effect of
disrupting the gut microbiome at various host life stages [265]. The use of
antibiotic-treated mice is easily attainable and maintained with minimal costs but
does not allow complete control of microbial population and elucidation of
specific host-microbe interactions [265]. Furthermore, there is the potential of
drug-pollutant interactions that could influence the actions of PCBs and/or
antibiotics. Another, more rigorous, method of elucidating the role of the
microbiota is to use germ free mouse models. The terminology germ free is
defined as an animal free of bacteria, viruses, fungi, parasites, and protozoa from
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birth [266]. The use of a germ-free mouse model to examine PCB-induced
toxicity would allow us to understand the role that the microbiota in a
mechanistic, more extreme sense. While this model will provide further insight
into host-microbe interactions in PCB exposure, due to the extreme nature of this
model, it can lack translatability. GF mice often need to be supplemented with
vitamins, specifically K and B, and have a less developed and less functional
small intestine, making energy absorption and utilization less efficient [266].
While utilizing GF models will provide us with critical information on the microbial
influence of PCB toxicity, due to our labs interest on cardiometabolic disease and
pollutant exposure, a logical next step would be the utilization of gnotobiotic
mouse models. Gnotobiotic, derived from the Greek “gnōtos” (known) and
“biotic” (life), simply means that GF mice are colonized with a specific microbial
population, often from humans, to generate a humanized mouse model [267].
Humanized mouse models developed from GF mice have been used in a variety
of areas of research including those focusing on cardiovascular diseases,
neurological diseases, and metabolic diseases [267]. Thus, our lab could utilize
the microbial population taken from individuals with
cardiovascular/cardiometabolic disease and develop gnotobiotic mouse models
to better understand the interactions between host physiology and a dysbiotic
microbiota. Employing this method would provide us with the most translatable
data, regarding the microbiota, to date and allow us to explore novel mechanisms
of pollutant toxicity and develop interventions that better target these
mechanisms. The use of the above discussed methods in a stepwise fashion
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could allow us to garner critical data regarding host-microbe-pollutant interactions
that examine a range potential mechanisms.
Another future direction for the laboratory could be to look more into the
effects of PCBs and dietary fiber on gut microbial derived metabolites that reach
peripheral circulation. One of the primary mechanisms that the gut microbiota
influence host health outcomes is through the generation of metabolites that can
exert differential effects on various host tissues [173]. The most understood
metabolites produced by the gut microbiota are short chain fatty acids (SCFA),
but there are numerous other metabolites that have not been explored or even
discovered. Discovery of novel microbial derived metabolites from PCB and/or
fiber exposure could open new avenues of exploration of the mechanisms by
which PCBs exert their toxicity and the observed protective effects that we
observed with fiber consumption.
Our lab has extensive expertise in examining the protective effects of
polyphenols against pollutant-induced toxicity. Because dietary fiber and
polyphenolic compounds are found predominantly in plant matter (i.e. fruits and
vegetables), examining the potential of these compounds in combination could
be greatly efficacious and highly translatable to the human population. The aryl
hydrocarbon receptor (AhR) is critical in gut health and intestinal immunity [268].
However, as discussed throughout this dissertation, PCBs exert their effects
through strong binding to AhR, leading to the upregulation of cytochrome p450
(Cyp1a1) and production of reactive oxygen species that lead to cellular
dysfunction and inflammation [2]. It has been demonstrated that certain gut
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microbial derived metabolites can act as AhR agonists and/or antagonists [269].
Importantly, it was found that the tryptophan metabolite indole functioned as an
AhR antagonist and inhibited 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced
Cyp1a1 expression [270]. Gut microbial derived tryptophan metabolites, as
discussed in chapter one, of this dissertation have been demonstrated to exert
protective effects on intestinal immunity and overall host health [94, 96, 98, 270].
High levels of tryptophan can be found in numerous food products, both animal
and plant derived. One of the highest tryptophan content plant foods is broccoli,
which also is high in dietary fiber [95]. Because of our discovery that fiber
consumption can be protective against PCB-induced toxicity and the known
effects of tryptophan metabolites, a combination of these could be highly
therapeutic as well as translatable.
In conclusion, this dissertation demonstrates that exposure to PCB 126
exerts deleterious effects on gut microbiota both directly through membrane
disruptive mechanisms and indirectly through inflammatory mechanisms within
the gut and peripherally. Our lab has previously shown that nutritional
interventions, specifically polyphenol consumption is able to modulate the toxicity
of PCBs and thus, are a potential means by which to prevent toxicant-induced
diseases [73, 264]. To expand the scope of nutritional modulation of pollutant
toxicity beyond just polyphenols, in this dissertation we have shown that
consumption of prebiotic dietary fiber is not only able to attenuate PCB-induced
changes in the gut microbiota, but also able to prevent against peripheral
inflammation and hepatic steatosis. Taken together, the data presented in this
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dissertation support the growing body of literature indicating that use of dietary
prevention and/or intervention measures may be a practicable approach to
diminish disease risks associated with environmental pollutant exposure.
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